

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

BMJ Open

BMJ Open

A randomized controlled trial of virtual reality-based distraction for venipuncture-related distress in children

Journal:	BMJ Open
Manuscript ID	bmjopen-2021-057892
Article Type:	Protocol
Date Submitted by the Author:	01-Oct-2021
Complete List of Authors:	Ali, Samina; University of Alberta, Pediatrics Rajagopal, Manasi; University of Alberta, Pediatrics Stinson, Jennifer; Toronto SickKids Ma, Keon; University of Calgary Cumming School of Medicine, Pediatrics Vandermeer, Ben; University of Alberta, Pediatrics Felkar, Bailey; London Health Sciences Centre, Pediatrics Schreiner, Kurt; University of Alberta, Pediatric Parents' Advisory Group Proctor, Amanda; Alberta Health Services Plume, Jennifer; Alberta Health Services Hartling, Lisa; University of Alberta, Pediatrics
Keywords:	ACCIDENT & EMERGENCY MEDICINE, Pain management < ANAESTHETICS, Paediatric A&E and ambulatory care < PAEDIATRICS, PAIN MANAGEMENT
	·



<u>Title:</u> A randomized controlled trial of virtual reality-based distraction for venipuncturerelated distress in children Lay Title: Virtual Reality Based Distraction for Painful Procedures in Children

<u>Authorship:</u> Samina Ali MDCM^{1,2,*}, Manasi Rajagopal MBT¹, Jennifer Stinson³, Keon Ma MD⁴, Ben Vandermeer MSc⁵, Bailey Felkar MS CCLS⁶, Kurt Schreiner MPM⁷, Amanda Proctor⁸, Jennifer Plume BM, MA MTA⁹, Lisa Hartling PhD^{1,5}

1 Department of Pediatrics, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Alberta, Canada

2 Women & Children's Health Research Institute, University of Alberta, Edmonton, Alberta, Canada

3 Child Health Evaluative Sciences, Research Institute, The Hospital for Sick Children and the Lawrence S. Bloomberg Faculty of Nursing, University of Toronto, Toronto, Ontario, Canada

4 Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada

5 Alberta Research Centre for Health Evidence, Department of Pediatrics, University of Alberta, Edmonton, Alberta, Canada

6 London Health Sciences Centre Children's Hospital, London, Ontario, Canada

7 Pediatric Parents' Advisory Group, University of Alberta, Edmonton, Canada

8 Stollery Youth Advisory Council and Patient and Family Centred Care, Edmonton, Alberta, Canada

9 Stollery Children's Hospital, Edmonton, Alberta, Canada

*denotes corresponding author, and contact for public and scientific inquiries 3-583 Edmonton Clinic Health Academy 11405 – 87 Avenue Edmonton, AB T6G 1C9 Phone: (780) 248-5574

Phone: (780) 248-5574

Fax: (888) 775-8876

Email: sali@ualberta.ca

Keywords: virtual reality, distress, pain, distraction, pediatrics, intravenous

Trial Protocol Version 15 July 2020 Trial Registration: clinicaltrials.gov NCT04291404 WHO Trial Registration Data Set: See Table 1

Word Count: 3968/ 4000 words

Ali S, Rajagopal M, et al

ABSTRACT

Introduction. Intravenous (IV) insertions are among the most commonly performed procedures for children seeking medical care; they are often a painful and stressful experience for both children and their caregivers. Pediatric distress and pain that is inadequately treated may lead to a frightened and uncooperative child, repeated IV attempts and overall frustration with care for both the family and clinical team. We hypothesize that distraction via an immersive virtual reality (VR) experience may reduce the associated distress for children undergoing IV insertions.

Methods and analysis.

This two-armed randomized controlled superiority trial will be conducted in a Canadian pediatric emergency department and will aim to enroll 80 children overall. Children will be randomized to receive either departmental standard of care alone or standard of care plus an immersive VR experience. Children 6 to 17 years of age who are undergoing IV insertion and have topical anesthetic application will be considered for inclusion. Our primary objective is to compare the reduction of distress between the two study arms. The primary outcome will be the child's observed distress score as measured by the Observational Signs of Behavioral Distress-Revised (OSBD-R) tool. Secondary outcomes include the child's pain intensity and fear, parental anxiety, satisfaction with the IV procedure, as well as adverse events. Recruitment launched in September 2020 and is expected to end in January 2022.

Ethics and dissemination. This study has been approved by the Health Research Ethics Board (University of Alberta). Informed consent will be obtained from parents or guardians, and assent from children. Study data will be submitted for publication irrespective of results. This study is funded through a Women and Children's Health Research Institute Innovation grant. Purchase of the VR equipment was facilitated through a Stollery Children's Hospital Foundation small equipment grant.

Trial registration number: NCT04291404, First registered March 02, 2020

Words: 300/ 300

Article Summary Strengths and limitations of this study

- 1. This randomized controlled trial will assess the effectiveness of immersive virtual reality-based distraction for the reduction of IV insertion-related distress in children.
- 2. This study measures patient- and family-relevant outcomes including child distress, pain, fear and safety as well as parental anxiety and satisfaction.
- 3. The study team includes parent and patient partners as co-investigators who will inform study methods and outcomes.
- 4. The study intervention will be compared to current standard of care; however since there is no consistent standard of care distraction practice, this may create some heterogeneity in the comparison arm of the study.
- 5. Given the nature of the study intervention, it is not possible to blind patients, parents/caregivers, health care providers, or outcome assessors; the statistician will be blinded to study arms.

INTRODUCTION

Needle procedures, including venipuncture and intravenous (IV) placement, are described by children as some of the most distressing and painful parts of their healthcare visit. [1-5] Untreated distress and pain can lead to a scared and uncooperative child, a need for repeated IV attempts, reduced efficiency and overall dissatisfaction with care for the patient, family and the health care team. [4, 6, 7] Unpleasant medical encounters in childhood can also shape an individual's perception of healthcare and expectations of pain in adulthood. [4, 8-10] This can result in increased anticipatory anxiety and pain for future medical procedures or an avoidance of healthcare services, altogether. [1] As needle procedures form a routine and necessary part of care in the emergency department (ED) [11], it is an important responsibility of health care providers to adequately manage children's distress and pain, wherever possible.[12]

The recommended and responsible approach to managing children's procedural pain incorporates physical, psychological, and pharmacological components. [13-16] While pharmacological interventions such as topical anesthetic creams are available, their effectiveness is limited to *pain*, as they do not address procedure-related *distress and* anxiety. [13] Distraction therapy is a commonly employed psychological strategy which involves engaging children in a cognitive task or activity in order to divert attention away from nociceptive stimuli. [17] An effective distractor provides sensory stimulation and is highly engaging and age-appropriate in order to fully capture the attention of a child. [11] Previous research has indicated that children who use distraction as an active form of coping experience reduced pain and distress during painful procedures. [11, 18, 19] Traditional distraction techniques such as music, video, stories, imagery and focused breathing have been previously explored for children undergoing unpleasant medical procedures and demonstrated mixed results. [20-25] Our team's recently conducted systematic review of digital technologies has suggested that digital distraction techniques appear promising, but require further study to confirm their utility for painful procedures. [26]

Virtual Reality (VR) technology is rapidly emerging as a novel distraction tool for children undergoing various medical procedures. Unlike traditional distraction techniques, VR uses a combination of visual, auditory and tactile stimuli to create the illusion of being fully immersed in an artificial three-dimensional environment. [27] A Head Mounted Display (or 'VR goggles') delivers the VR video and audio to the child, and also serves to block out the view and sounds of the hospital room. [13] This further removes the patient from the chaos of the treatment room and diverts their attention away from surrounding painful and anxiety-evoking stimuli. To date, VR distraction therapy has shown promise for patients undergoing a range of distressing healthcare procedures, including burn wound cleaning, chest radiography, dental interventions and chemotherapy. [28-33] Therapeutic VR has also led to improved health outcomes for patients with anxiety disorders, phobias, post-traumatic stress disorder, and eating disorders. [34-37]

60

Due to the chaotic, noisy and unpredictable environment of the ED, it is an ideal place to 'stress-test' the ability of VR technology to immerse a child into a distracting and 'safe' space while having a medical procedure. Rapid advances in VR technology over the last few years, and improved cost-effectiveness, offers a unique opportunity to explore its use in the ED setting. While recently published studies from the ED setting suggest that there is a positive impact when VR is used for IV insertion in children, [11, 13] recent systematic reviews have concluded that the current evidence is inconclusive. [38] Furthermore, outcomes such as distress and adverse effects remain poorly studied. [38] Many previous trials utilize proprietary software designed specifically for medical use which may limit widespread accessibility to all centers. This study will evaluate an "off-the-shelf" device with a range of widely accessible software.

This study will evaluate the effectiveness of a VR intervention in reducing IV placementrelated distress for children 6-17 years old presenting to the ED. We hypothesize that the use of immersive VR distraction will reduce children's IV related distress when compared with standard of care, and will improve overall satisfaction with the procedure for the patient, family and the health care team.

METHODS AND ANALYSIS

The Virtual Reality Study Protocol Version 1.0

This study is a two-armed, randomized, controlled superiority trial. The study protocol is reported using the SPIRIT-PRO reporting guidelines. [39] (See Table 1.)

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Table 1. WHO Trial Registration Data Set

Data Category	Information
Primary Registry and Trial	clinicaltrials.gov NCT04291404
Identifying Number	
Date of Registration in	March 2, 2020
Primary Registry	
Secondary Identifying	University of Alberta Research Ethics Board #
Numbers	Pro00095418
Source(s) of Monetary or	Stollery Children's Hospital Foundation and the
Material Support	Women and Children Health Research Institute
	Innovation Grant
Primary Sponsor	University of Alberta
Secondary Sponsor(s)	-
Contact for Public Queries	Dr. Samina Ali 780.248.5575 sali@ualberta.ca
Contact for Scientific Queries	Dr. Samina Ali 780.248.5575 sali@ualberta.ca
Public Title	The Virtual Reality Trial
Scientific Title	A randomized controlled trial of virtual reality-based
	distraction for venipuncture-related distress in children
Countries of Recruitment	Canada
Health Condition(s) or	Venipuncture-related distress
Problem(s) Studied	
Intervention(s)	Addition of distraction via an immersive virtual reality
	experience to departmental standard of care during the
	intravenous (IV) insertion procedure
Key Inclusion and Exclusion	To be eligible to participate in this study, an individual
Criteria	must meet all of the following inclusion criteria: (a)
	child aged 6–17 years; (b) requires IV placement; and
	(c) will receive topical anesthetic cream for IV
	placement. Children meeting any of the following
	criteria will be excluded: (a) medically unstable; (b)
	unconscious or not fully alert; (c) visual, auditory
	cognitive, or mental health issues precluding safe
	interaction with the VR intervention; (d) conditions
	that could be exacerbated by the VR environment,
	such as <i>current</i> symptomatic nausea / vomiting / dizziness/migraine, or a <i>history</i> of
	psychosis/hallucinations/epilepsy; (e) presence of an
	infection/injury which could contaminate the VR
	intervention equipment such as open wounds/
	infections of the head and neck area, or
	suspected/confirmed methicillin-resistant
	Staphylococcus aureus colonization; (f) screens
	positive for 'influenza-like illness' as per departmental
	screening criteria; (g) language barrier precluding the
	ability to understand and complete study assessments,
L	

	in the absence of a native language translator; or (h)
	previous enrollment in this study.
Study Type	Randomized Controlled Superiority Trial
Date of First Enrollment	October 5, 2020
Sample Size	80
Recruitment Status	Actively recruiting
Primary Outcome(s)	The primary outcome will be the child's total observed distress score during the IV procedure as measured on the Observational Signs of Behavioral Distress- Revised (OSBD-R) tool.
Key Secondary Outcomes	Secondary outcomes include: (a) the child's self- reported pain score during the IV procedure, using an 11-point 0-10 verbal Numerical Rating Scale (vNRS); (b) the child's self-reported fear score during the IV insertion as measured by the Children's Fear Scale (CFS); (c) parental/caregiver anxiety associated with the procedure, as assessed by the State Trait Anxiety Inventory - State Trait Revised Version (STAI-S, Form Y); (d) satisfaction with the procedure for the child, their parent/caregiver and the nurse inserting the IV, as assessed by a 5-point Likert scale; and (e) the proportion of children who experience adverse events related to the study intervention.
Ethics Review	University of Alberta Research Ethics Board # Pro00095418
Completion date	-
Summary Results	-
IPD sharing statement	De-identified data can be shared, on a case-by-case basis, upon discussion with the principal investigator.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Setting and Study Period

This study will be conducted in the Stollery Children's Hospital (SCH) emergency department in Edmonton, Alberta, Canada. The SCH is a tertiary care hospital whose annual ED census is typically approximately 60,000. The 2020 ED census for the SCH was reduced to 36,899 due to the COVID-19 pandemic. Study recruitment commenced on September 28, 2020. Based on our team's previous experience conducting research in this setting, and considering the ongoing pandemic-related considerations, we anticipate 18 months of recruitment to meet our overall target of 80 patients.

Eligibility and Exclusion Criteria

Children will be eligible if they are 6 to 17 years, require an IV placement during their ED visit, and have received topical anesthetic cream for their IV placement. This age group was chosen as they are able to reliably self-report pain and are expected to benefit from the virtual reality study intervention, based on prior studies. [40] Due to ethical and pragmatic considerations, we insisted that children must be receiving topical anesthetic cream for IV placement to be eligible for our study, as it is effective and considered standard of care within our hospital. [14] Exclusion criteria are detailed in Table 1.

Study Intervention and Comparison

The intervention will include the use of an immersive VR application that will engage children for the duration of the IV procedure. The VR intervention will be provided in addition to standard of care. The child will wear the VR goggles (Oculus Ouest, Oculus, Facebook Technologies, LLC; see Figure 1) and small handheld controllers (optional) can be used to interact with the virtual environment and change settings. The VR goggles will occlude the patient's view of the treatment room, and a pair of noise-cancelling headphones (optional) can be used to block out ambient hospital sounds. Together, this will provide the child with a unique vivid experience of being fully immersed or "present" inside the 3D virtual world. The child will be presented with one of two VR menu options, one for novice users and another for more experienced users. The menus will have pre-selected VR applications that are suitable for use during the IV procedure and will include a combination of interactive games and immersive 3D movies designed specifically for a virtual reality experience (see Figure 2). The choice of applications was based on consultation with the Stollery Children's Hospital Youth Advisory Committee prior to commencing the study. The shortlisted applications were then tested by the principal investigators, other team members, and youth. The research assistant (RA), who will be trained in proper equipment use and trouble-shooting, will help the child with selecting and running the VR game/movie. Based on child and nursing preference, children may either sit up or lie in a supine position for the duration of the procedure. The chosen VR games will not require the child to move their torso or both arms, so as to not interfere with the IV placement. The VR goggles can be removed at any time during the procedure, if the child so desires.

The control group will receive departmental standard of care which will include topical anesthetic cream (mandatory for inclusion in the study) and may include parent/caregiver support, child life services, nursing support, and other support strategies at the discretion of the ED clinical care team and the family. At present, there is no single established

distraction therapy or routine that is consistently employed for IV procedures within our ED. Thus, for pragmatic and ethical considerations, it is felt that the new study VR intervention should be compared to what is currently already in practice (i.e. standard of care). Generally, VR technology is not employed by the nursing staff for distracting the child. However, other forms of technology (i.e., smart phones, tablets) will *not* be prohibited in the control group if the family chooses to offer them. Use of other devices and distraction techniques will be documented.

Randomization, Allocation Concealment, and Blinding

Randomization will be determined using an online randomization tool hosted on the REDCap [42] (Research Electronic Data Capture) platform. Following documentation of informed consent and assent, the RA will obtain the computer-generated randomized assignment for the child by clicking on the 'Randomize' button within the study-specific REDCap case report form. Allocation will be concealed from the research staff, ED clinical staff and the family until this point. However, due to the nature of the intervention, it is not possible to maintain blinding once the child has been randomized.

Children and their parents/caregivers will be informed that the study will evaluate and compare different forms of distraction, however they will not be made aware of the study hypothesis for the VR intervention. [7] Furthermore, the statistician will be blinded to treatment assignment by using randomization codes until data analysis is complete.

Recruitment and Data Collection

The Virtual Reality Study Protocol Version 1.0

Participant recruitment will occur in the SCH ED when RAs are on-site, from approximately 15:00 to 23:00 daily. Based on our team's previous research, this time frame corresponds with peak ED volume. RAs will screen the electronic ED track board and communicate with on-site clinical staff to identify potentially eligible patients. The RA will then further assess eligibility based on the inclusion/exclusion criteria detailed above. If the child is deemed eligible and the family is willing to participate, the RA will obtain written informed consent from the parent/ caregiver and assent from the child (See Appendix 1). One parent/caregiver for each child will be asked to provide consent and complete all relevant study questionnaires.

Prior to the beginning of the IV procedure, the RA will collect baseline information, including: baseline heart rate, pre-procedure distress, fear, and pain scores from the child, and pre-procedure anxiety score from the parent/caregiver. The RA will then access the randomization tool on REDCap to reveal the child's group assignment (VR intervention or Control).

For the VR intervention group, the RA will set up the VR equipment and spend approximately 5-10 minutes explaining the intervention to the child, including proper use of the goggles and controller. The RA will then help the child put on and secure the goggles and headphones, and hand them the controller. They will document the time required for equipment set up as well as any technical challenges encountered. As per hospital infection control policy, all VR equipment including the goggles, headphones

and controller will be sanitized with disinfectant wipes between participants. A disposable one-time use cover will be placed on the goggles for each participant. For all participants (both study arms), the RA will begin video recording the child five minutes prior to the start of the procedure and continue until 5 minutes post-procedure, to allow for complete coding of OSBD-R distress scores at a later time.

For all participants (both study arms), the staff nurse will insert the IV following institutional protocol. In keeping with the pragmatic design of the trial, no additional or study-specific instructions will be provided to either nurses or parents/caregivers regarding their behaviour during the procedure. For purposes of the study, the start of the IV insertion procedure will be marked by the cleaning of the IV site by the staff nurse. The end of the procedure will be defined by the last point of contact by the staff nurse (i.e., taping cannula in place with or without arm board, wrapping arm with gauze and taping the gauze in place).

During the procedure, the RA will closely monitor the child for any adverse effects. The child will also be asked to let the team know immediately if they are experiencing any adverse events or discomfort related to the VR intervention (i.e., dizziness, nausea, headache). The VR intervention can be discontinued (i.e., the headset can be removed) at any time, at the discretion of the child or clinical team. If an adverse event were to occur, the clinical team will be notified, and details will be logged in the REDCap adverse event log. Additionally, the RA will make a note of any technical failures or issues associated with the VR equipment during enrollment.

Immediately following the first *attempt* at IV placement (regardless of whether it was successful), the RA will collect post-procedure distress, fear and pain scores from the child, and post-procedure anxiety score from the parent/caregiver. A few minutes after completion of the IV placement, satisfaction and acceptability questionnaires will be completed with the child, parent_caregiver as well as the staff nurse responsible for

inserting the IV. Five minutes after the procedure is completed, the RA will stop the

video recording. The duration of the procedure and total number of IV attempts will be documented. If the first attempt at placement is unsuccessful, any additional attempts will occur after all relevant study questionnaires/measurements have been completed.

Demographic information, previous history and visit details will also be collected from the family and the child's medical chart. See Figure 3 for study flow schematic.

Outcome Measures

Our primary outcome is **distress**. Our secondary outcomes are (**a**) pain; (**b**) fear; (**c**) the parental/caregiver anxiety; and (**d**) parental/caregiver and nurse satisfaction with the procedure in the intervention; and (**e**) safety.

Our primary outcome measure will be the child's total distress score during the IV procedure. Distress associated with the procedure will be assessed using the

Observational Scale of Behavioral Distress-Revised (OSBD-R). The OSBD-R is a validated scale that is widely used to measure pain and distress associated with various medical procedures in children. [43-45] The tool assesses eight specific behaviors that are indicative of distress and are weighted according to intensity: information seeking, crying, screaming, restraint, verbal resistance, emotional support, verbal pain, and flailing. Study participants will be videotaped for the duration of the IV procedure as well as for a few minutes before and after; distress will be scored pre-, during, and postprocedure. Two RAs who are trained in the use of the tool will independently observe the videotapes and record the frequency of each of the eight behaviors during continuous 15second intervals. To ensure high inter-rater reliability, the first 10% of coded videos will be analyzed for inter-rater reliability and RAs will be provided with feedback and retraining, as needed, prior to coding the remaining videos. [7] The mean OSBD-R scores between the two RAs will be used as the final scores. This standardized procedure for OSBD-R has been successfully used in previous research evaluating distraction. [30, 43, 46-49] This scale demonstrates high inter-rater reliability as well as moderate to high correlations with other behavioral measures of distress. [46, 50, 51] Our principal secondary outcome measure will be the child's pain score during the IV procedure. Pain will be measured using an 11-point verbal Numerical Rating Scale (vNRS) ranging from 0 (no pain) to 10 (worst possible pain). This scale is a commonly used pain measurement tool in pediatric acute pain studies and is validated for use in children 6-17 years of age. [52-55] Pain scores will be self-reported by children both before and immediately following the IV procedure. Fear will be measured using the Children's Fear Scale (CFS) [5, 56]. This scale depicts five faces representing increasing levels of anxiety, where the left-most face depicts "not scared at all" (score=0) and the right most-face means "most scared possible" (score=4). The CFS is an adaptation of the adult Faces Anxiety Scale [56] and has been validated to measure fear in children undergoing painful medical procedures. [5] Children will be asked to independently rate their fear both before and immediately following the IV procedure. Parental/Caregiver anxiety will be measured with the State Trait Anxiety Inventory – State Scale Revised Version (STAI-S, Form Y), a validated and commonly used version of STAI, which has improved psychometric properties. [57] Parents/caregivers will be asked to complete the STAI questionnaire both before and immediately following the IV

Parent/caregiver and nurse satisfaction with the procedure will be measured using a 5-point Likert scale, ranging from 1 "Very dissatisfied" to 5 "Very satisfied". Child satisfaction with the procedure will be measured using a 5-point Likert scale, ranging from 1 "Not at all happy" to 5 "Very happy". Satisfaction scores will be collected immediately following the IV procedure.

procedure.

Safety of the VR intervention will be determined by assessing the frequency of adverse events post intervention. Specifically, nausea will be self-rated by children immediately following the intervention, using the Baxter Retching Faces (BARF) scale [58]. This scale consists of 6 faces depicting increasing levels of nausea, with assigned scores ranging from 0 to 10. The BARF scale is widely used in medical research and has demonstrated construct, content and convergent validity as a tool to measure nausea in children. The presence of other adverse events (i.e., dizziness) will also be recorded by the RA. Children who are presenting with nausea, vomiting, dizziness or migraines *prior* to enrollment will be excluded from the study to avoid exacerbating these conditions with the use of the VR equipment.

Sample Size

The sample size for the study is 80 patients overall. Sample size calculations were conducted using a two-tailed, two-sample Mann-Whitney test for the primary outcome of observed behavioral distress based on data from the team's previous trial of digital distraction. To detect a large effect size of 0.6 on the OSBD-R (which was observed in a previous trial), given a Type I error of 0.05 and 80% power, the study will require 35 patients for each of the two study arms. To account for attrition and technical recording failures, the team will plan to over-recruit by 10-15%, for an overall total of 80 patients. This will allow sufficient power to find a difference in the primary outcome, if a difference truly exists.

Statistical Methods

Statistical analyses will be conducted using statistical software SAS (version 9; SAS Institute, Cary, NC). The significance level will be set at 0.05. Baseline variables will be described using appropriate summary statistics for each group. Imbalances between groups for key baseline variables will indicate the need for further adjusted analyses. For the primary outcome of observed behavioral distress, total OSBD-R scores will be compared between the two groups using independent samples t-tests if they are normally distributed or Mann-Whitney U-tests if they are skewed (the Sidak correction procedure will be used to reduce the probability of a Type I error). Additional model-based analyses (multiple linear regression) will be conducted, as needed, with behavioural distress as the response variable, pre-procedure behavioral distress and group indicators as the explanatory variables along with some possible effect modifiers such as age, sex, and parental/caregiver anxiety levels. Our primary analysis will be based on an intention-totreat approach where all children who were randomly assigned to a study group will be included in the group to which they were randomized. Where cell sizes are small or data are sparse or missing, proxy information or appropriate imputation methods will be used as needed. Similar approaches will be used to compare the groups with respect to secondary outcomes if appropriate.

Patient and Public Involvement

The team's parent advisor (KS) has provided ongoing input on the study protocol and design, and has provided valuable feedback on the content, flow and readability of the consent forms and data collection forms. The Stollery Youth Advisory Council, led by team member AP, provided input on the study design, outcomes measures, and types of

Page 13 of 53

The Virtual Reality Study Protocol Version 1.0

virtual reality applications that might be engaging and practical for our study population. AP also reviewed the study protocol and related documents to ensure that the outcomes and tools were patient-relevant and age-appropriate. Following recruitment completion, parent and youth advisors will be further engaged to discuss study results and dissemination plans in the context of patient- and family-centered care.

Data Management and Confidentiality

Data will be entered into a secure online REDCap [42] database hosted by the Women and Children's Health Research Institute (WCHRI). (See Appendix 2 for Case Report Form.) WCHRI's REDCap installation is a validated electronic, web-based data capture system housed in a secure data center at the University of Alberta. Data is entered into REDCap through a web-based interface using 128-bit SSL encryption. Each team member will be granted an individual username/ password and will require additional two factor authentication to log in. All datasets used for statistical analysis will be encrypted and devoid of any patient identifiers. For internal data quality control, a secure master list will be maintained to accurately link study IDs to the patient's medical record.

Selected data elements will be validated electronically throughout the recruitment period and any discrepancies will be assigned to team members for timely resolution. REDCap includes internal quality checks, such as automatic range checks, to identify data that appear inconsistent, incomplete, or inaccurate.

Study data will be entered directly into REDCap in real-time via research iPads or, in some cases (i.e., parent/caregiver indicate a preference to complete paper-based questionnaires), responses may be collected on paper first and then transcribed into REDCap by a trained RA. All paper documents (including study questionnaires, consent/assent forms, and the master list) will be stored in a locked cabinet in a secure location that is only accessible to authorized research staff members. Study videos will be stored electronically in a secure institutional shared drive with restricted access to study staff. Videos will be stored on a secure server and computers at the University of Alberta. Following completion of the study, all data will continue to be kept in a secure location for five years as dictated by the research ethics board.

ETHICS AND DISSEMINATION

This study has received approval from the Health Research Ethics Board (HREB) at the University of Alberta (HREB identifier: Pro00073476). Any amendments to the study protocol or documents will be submitted for HREB review and will receive approval prior to implementation. Significant protocol amendments will also be reflected online on the clinicaltrials.gov study registration. This study has also received operational approval from the SCH ED.

All children will receive the best possible care for their presenting complaint, regardless of whether they choose to participate. It is possible that patients in the VR intervention group may experience nausea, mild motion sickness or dizziness, however these effects

are rare in children and adolescents, ranging from 0-5%. [59, 60] VR applications have been selected appropriately to minimize these discomforts, and children are monitored closely throughout the study for any adverse effects. Children experiencing nausea, vomiting, dizziness or migraine headaches prior to enrollment will be excluded to avoid potential exacerbation. Study participation is unlikely to prolong the ED length of stay. For infection-control purposes, children screening positive for 'influenza-like illness' (as per ED screening criteria) are excluded to prevent potential contamination of the VR equipment.

Due to resource/logistical constraints, study recruitment will be limited to Englishspeaking families or those with their own interpreter, at a single recruiting center, and during RA shift hours only. Critically ill children requiring immediate IV insertion will also be excluded to avoid delaying medical care. This may limit the generalizability of the study findings. We will not be controlling for the type of distraction used in the standard of care arm, but we will record what was employed. While this may create some heterogeneity in the comparison arm of the study, it will be a pragmatic reflection of clinical reality. Due to the nature of the intervention, blinding is not possible for the participants or the research personnel, though the statistician will be blind to study group.

The study team plans to publish trial results in a high-impact, peer-reviewed journal and present results at national and international meetings; authorship eligibility will be determined by employing the International Committee of Medical Journal Editors' recommended guidelines. [61] Statistical code and dataset can be made available upon request.

Competing Interests None declared.

Patient Consent After assessing eligibility based on the outlined inclusion/exclusion criteria, research assistants will obtain consent from the parents/caregivers (and assent from children older than 6 years) prior to enrolling the child in the study. The research assistant will provide both a verbal and written explanation of the study to the family. The family will be given an opportunity to review the consent/assent forms in private and can ask the research assistant any questions they might have prior to signing the consent/assent forms. The family is free to withdraw at any point during the study.

<u>Acknowledgments</u> The authors would like to thank the members of the Stollery Youth Advisory Council, who provided valuable input on the study design and gaming/application choices for the virtual reality headsets.

FUNDING STATEMENT

This work is funded by the generosity of the Stollery Children's Hospital Foundation through the Women and Children's Health Research Institute Innovation Grant. Purchase of the virtual reality goggles was facilitated through a generous small equipment grant

The Virtual Reality Study Protocol Version 1.0

from the Stollery Children's Hospital Foundation. The funders do not have any role in the collection, management, analysis, or interpretation of data; writing of the report; or the decision to submit the report for publication. Dr. Hartling is supported by a Canada Research Chair in Knowledge Synthesis and Translation and is a Distinguished Researchers with the Stollery Science Lab supported by the Stollery Children's Hospital Foundation.

for beer terien only

AUTHOR CONTRIBUTIONS

Dr. Samina Ali (SA) is a pediatric emergency clinician-researcher and Professor of Pediatrics & Emergency Medicine at the University of Alberta. She co-developed and revised the protocol and co-drafted the protocol paper. She chose the previously validated tools for measuring the primary outcomes.

Manasi Rajagopal (MR) is the program lead for the Pediatric Emergency Medicine research program at the University of Alberta and co-principal investigator of this study. She co-developed the study protocol, co-drafted the protocol paper, and will operationalize the study.

Dr. Jennifer Stinson (JS) is the Mary Jo Haddad Nursing Chair in Child Health at the Hospital for Sick Children's Research Institute and a nurse practitioner in the Department of Anesthesia's chronic pain program at the hospital. She assisted with the study design and protocol revision.

Dr. Keon Ma is a pediatric trainee at the University of Calgary, with expertise in OSBD-R coding. He assisted with the study design and protocol revision.

Ben Vandermeer (BV) led the statistical analysis planning and contributed to protocol revision.

Bailey Felkar (BF) is a child life specialist at the Stollery ED with expertise in managing children's pain and distress in the ED setting. She assisted with the study design and protocol revision.

Kurt Schreiner (KS) is a family partner who has provided input into study outcomes to ensure family-relevant outcomes are chosen and will inform our knowledge translation efforts to the public.

Amanda Proctor (AP) is the coordinator of the Stollery Youth Advisory Council. Together with the council, she informed programming choices for the virtual reality devices and has reviewed the protocol and related documents to ensure that the outcomes and tools are patient-relevant and age-appropriate.

Jennifer Plume (JP) is the acting director for Stollery child life services with expertise in managing children's pain and distress in the ED. She has informed study methods and will aid and support the development of our knowledge translation plan.

Dr. Lisa Hartling (LH) is a Professor in the Department of Pediatrics at the University of Alberta and Director of the Alberta Research Centre for Health Evidence (Edmonton, Canada). She assisted with the study design and drafting the protocol, and provides expertise in clinical trial methodology and statistical analyses.

The Virtual Reality Study Protocol Version 1.0

All authors have approved this final version of the protocol. None of the authors have financial or other conflicts of interests as they pertain to this study and its involved recruitment sites.

For beer terien only

Figures Legend

Figure 1. Child using virtual reality goggles in the emergency department **Figure 2.** Virtual Reality Game Menus **Figure 3.** Flow Diagram of Study Procedures

tor peer teriew only

The Virtual Reality Study Protocol Version 1.0

REFERENCES

- 1. Atzori B, Hoffman HG, Vagnoli L, et al. Virtual Reality Analgesia During Venipuncture in Pediatric Patients With Onco-Hematological Diseases, *Front Psychol* 2018;9 doi:10.3389/fpsyg.2018.02508.
- 2. Duff AJA. Incorporating psychological approaches into routine paediatric venepuncture, *Archives of Disease in Childhood* 2003;88:931-7 doi:10.1136/adc.88.10.931.
- 3. Caprilli S, Messeri A. Animal-Assisted Activity at A. Meyer Children's Hospital: A Pilot Study, *Evidence-based Complementary and Alternative Medicine* 2006;3:379 doi:10.1093/ecam/nel029.
- 4. Sanchez Cristal N, Staab J, Chatham R, et al. Child Life Reduces Distress and Pain and Improves Family Satisfaction in the Pediatric Emergency Department, *Clin Pediatr (Phila)* 2018;57:1567-75 doi:10.1177/0009922818798386.
- McMurtry CM, Noel M, Chambers CT, et al. Children's fear during procedural pain: Preliminary investigation of the Children's Fear Scale, *Health Psychology* 2011;30:780-8 doi:10.1037/a0024817.
- 6. McGrath PJ, McAlpine L. Psychologic perspectives on pediatric pain, *The Journal of Pediatrics* 1993;122:S2-8 doi:10.1016/S0022-3476(11)80002-8.
- 7. Ali S, Sivakumar M, Beran T, et al. Study protocol for a randomised controlled trial of humanoid robot-based distraction for venipuncture pain in children, *BMJ Open* 2018;8:e023366 doi:10.1136/bmjopen-2018-023366.
- 8. El-Housseiny AA, Alamoudi NM, Farsi NM, et al. Characteristics of dental fear among Arabic-speaking children: a descriptive study, *BMC Oral Health* 2014;14 doi:10.1186/1472-6831-14-118.
- 9. Fields H. How expectations influence pain, *Pain* 2018;159:S3-S10 doi:10.1097/j.pain.00000000001272.
- 10. Noel M, Rabbitts JA, Tai GG, et al. Remembering Pain after Surgery: A Longitudinal Examination of the Role of Pain Catastrophizing in Children's and Parents' Recall, *Pain* 2015;156:800 doi:10.1097/j.pain.00000000000102.
- 11. Dumoulin S, Bouchard S, Ellis J, et al. A Randomized Controlled Trial on the Use of Virtual Reality for Needle-Related Procedures in Children and Adolescents in the Emergency Department. , *Games for Health Journal* 2019;8:285-93.
- 12. Jain S, Hegenbarth MA, Humiston SG, et al. Increasing ED use of jet injection of lidocaine for IV-related pain management , *Pediatrics* 2017;139:e20161697.
- 13. Chan E, Hovenden M, Ramage E, et al. Virtual Reality for Pediatric Needle Procedural Pain: Two Randomized Clinical Trials, *The Journal of Pediatrics* 2019;209:160,167.e4 doi:10.1016/j.jpeds.2019.02.034.
- Trottier ED, Doré-Bergeron MJ, Chauvin-Kimoff L, et al. Managing pain and distress in children undergoing brief diagnostic and therapeutic procedures. [CPS Position Statement], *Paediatrics & Child Health* 2019;24:509-21.
- 15. Friedrichsdorf SJ, Eull D, Weidner CA. A Children's Comfort Promise: how can we do everything possible to prevent and treat pain in children using quality improvement strategies? *Pediatric Pain Letter* 2016;18:26-30.
- 16. Gaskell S. Evidence-based guidelines for the management of invasive and/or distressing procedures with children, *British Journal of Social Psychology* 2019.


- The Virtual Reality Study Protocol Version 1.0
- 17. McCaul KD, Malott JM. Distraction and coping with pain, Pain 1985;23:315.
- 18. Manne SL, Bakeman R, Jacobsen PB, et al. An analysis of a behavioral intervention for children undergoing venipuncture, *Health Psychology* 1994;13:556-66.
- 19. Vessey JA, Carlson KL, McGill J. Use of distraction with children during an acute pain experience, *Nursing Research* 1994;43:369-72 doi:10.1097/00006199-199411000-00009.
- 20. Klassen JA, Liang Y, Tjosvold L, et al. Music for Pain and Anxiety in Children Undergoing Medical Procedures: A Systematic Review of Randomized Controlled Trials, *Ambulatory Pediatrics* 2008;8:117-28 doi:10.1016/j.ambp.2007.12.005.
- 21. Cohen LL, Blount RL, Panopoulos G. Nurse Coaching and Cartoon Distraction: An Efective and Practical Intervention to Reduce Child, Parent, and Nurse Distress During Immunizations, *J Pediatr Psychol* 1997;22:355-70 doi:10.1093/jpepsy/22.3.355.
- 22. Cassidy K, Reid GJ, McGrath PJ, et al. Watch Needle, Watch TV: Audiovisual Distraction in Preschool Immunization, *Pain Med* 2002;3:108-18 doi:10.1046/j.1526-4637.2002.02027.x.
- 23. Downey LVA, Zun LS. The Impact of Watching Cartoons for Distraction During Painful Procedures in the Emergency Department, *Pediatric Emergency Care* 2012;28:1033 doi:10.1097/PEC.0b013e31826cac1a.
- 24. Young T, Griffin E, Phillips E, et al. Music as Distraction in a Pediatric Emergency Department, *Journal of Emergency Nursing* 2010;36:472-3 doi:10.1016/j.jen.2010.05.014.
- 25. Ha YO, Kim HS. The effects of audiovisual distraction on children's pain during laceration repair, *International Journal of Nursing Practice* 2013;19:20-7 doi:10.1111/ijn.12165.
- 26. Gates M, Hartling L, Shulhan-Kilroy J, et al. Digital Technology Distraction for Acute Pain in Children: A Meta-analysis, *Pediatrics* 2020;145 doi:10.1542/peds.2019-1139.
- 27. Ahmadpour N, Randall H, Choksi H, et al. international journal of biochemistry & cell biology, 2019;114:105568.
- 28. Sikka N, Shu L, Ritchie B, et al. Virtual Reality-Assisted Pain, Anxiety, and Anger Management in the Emergency Department, *Telemedicine and e-Health* 2019.
- 29. Hoffman HG, Doctor JN, Patterson DR, et al. Use of virtual reality for adjunctive treatment of adolescent burn pain during wound care: A case report, *Pain* 2000;1-2:305-9.
- 30. Han S, Park J, Choi SI, et al. Effect of Immersive Virtual Reality Education Before Chest Radiography on Anxiety and Distress Among Pediatric Patients: A Randomized Clinical Trial, *JAMA pediatrics* 2019 doi:10.1001/jamapediatrics.2019.3000.
- 31. Shetty V, Suresh LR, Hegde AM. Effect of Virtual Reality Distraction on Pain and Anxiety During Dental Treatment in 5 to 8 Year Old Children, *Journal of Clinical Pediatric Dentistry* 2019;43:97-102.
- 32. Furman E, Jasinevicius TR, Bissada NF, et al. Virtual Reality Distraction for Pain Control During Periodontal Scaling and Root Planing Procedures, *The Journal of the American Dental Association* 2009;140:1508-16 doi:10.14219/jada.archive.2009.0102.


- 33. Schneider SM, Hood LE. Virtual Reality: A Distraction Intervention for Chemotherapy, *Oncology nursing forum* 2007;34:39-46 doi:10.1188/07.ONF.39-46.
- 34. Gerardi M, Rothbaum BO, Ressler K, et al. Virtual reality exposure therapy using a virtual Iraq: Case report, *Journal of Traumatic Stress* 2008;21:209-13 doi:10.1002/jts.20331.
- 35. Parsons TD, Rizzo AA. Affective outcomes of virtual reality exposure therapy for anxiety and specific phobias: A meta-analysis, *Journal of Behavior Therapy and Experimental Psychiatry* 2008;39:250-61 doi:10.1016/j.jbtep.2007.07.007.
- 36. Botella C, Serrano B, Baños RM, et al. Virtual reality exposure-based therapy for the treatment of post-traumatic stress disorder: a review of its efficacy, the adequacy of the treatment protocol, and its acceptability, *Neuropsychiatr Dis Treat* 2015;11:2533-45 doi:10.2147/NDT.S89542.
- 37. Marco JH, Perpiñá C, Botella C. Effectiveness of cognitive behavioral therapy supported by virtual reality in the treatment of body image in eating disorders: One year follow-up, *Psychiatry Research* 2013;209:619-25 doi:10.1016/j.psychres.2013.02.023.
- Lambert V, Boylan P, Boran L, et al. Virtual reality distraction for acute pain in children, *The Cochrane database of systematic reviews* 2020;10 doi:10.1002/14651858.CD010686.pub2.
- 39. Chan A, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials, *Ann Intern Med* 2013;158:200-7 doi:10.7326/0003-4819-158-3-201302050-00583.
- 40. Hoffman HG, Rodriguez RA, Gonzalez M, et al. Immersive Virtual Reality as an Adjunctive Non-opioid Analgesic for Pre-dominantly Latin American Children With Large Severe Burn Wounds During Burn Wound Cleaning in the Intensive Care Unit: A Pilot Study, *Frontiers in human neuroscience* 2019;13 doi:10.3389/fnhum.2019.00262.
- 41. Gouin S, Gravel J, Amre DK, et al. Evaluation of the Paediatric Canadian Triage and Acuity Scale in a pediatric ED, *Am J Emerg Med* 2005;23:243-7 doi:10.1016/j.ajem.2004.02.046.
- 42. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support, *Journal of Biomedical Informatics* 2009;42:377-81 doi:10.1016/j.jbi.2008.08.010.
- 43. Jay SM, Elliott C. Observation Scale of Behavioral Distress-Revised. Information procedures, definitions of behaviors, OSBD Interval Coding Form. 1986.
- 44. Jay SM, Elliott C. Behavioral observation scales for measuring children's distress: The effects of increased methodological rigor, *Journal of Consulting and Clinical Psychology* 1984;52:1106-7 doi:10.1037/0022-006X.52.6.1106.
- Tucker CL, Slifer KJ, Dahlquist LM. Reliability and Validity of the Brief Behavioral Distress Scale: A Measure of Children's Distress During Invasive Medical Procedures, *J Pediatr Psychol* 2001;26:513-23 doi:10.1093/jpepsy/26.8.513.
- Elliott CH, Jay SM, Woody P. An Observation Scale for Measuring Children's Distress During Medical Procedures, *J Pediatr Psychol* 1987;12:543-51 doi:10.1093/jpepsy/12.4.543.

The Virtual Reality Study Protocol Version 1.0

47. Megel ME, Houser CW, Gleaves LS. Children's Responses to Immunizations: Lullabies as a Distraction, *Issues in Comprehensive Pediatric Nursing* 1998;21:129-45 doi:10.1080/014608698265456.

- Noguchi LK. The Effect of Music Versus Nonmusic on Behavioral Signs of Distress and Self-Report of Pain in Pediatric Injection Patients, *J Music Ther* 2006;43:16-38 doi:10.1093/jmt/43.1.16.
- 49. Hartling L, Newton AS, Liang Y, et al. Music to Reduce Pain and Distress in the Pediatric Emergency Department: A Randomized Clinical Trial, *JAMA Pediatrics* 2013;167:826-35 doi:10.1001/jamapediatrics.2013.200.
- 50. Stevenson MD, Bivins CM, O'Brien K, et al. Child Life Intervention During Angiocatheter Insertion in the Pediatric Emergency Department, *Pediatric Emergency Care* 2005;21:712 doi:10.1097/01.pec.0000186423.84764.5a.
- Jay SM, Ozolins M, Elliott CH, et al. Assessment of children's distress during painful medical procedures, *Health Psychology* 1983;2:133-47 doi:10.1037/0278-6133.2.2.133.
- 52. von Baeyer CL. Children's self-report of pain intensity: what we know, where we are headed, *Pain research & management* 2009;14:39.
- 53. Miró J, Castarlenas E, de la Vega R, et al. Validity of three rating scales for measuring pain intensity in youths with physical disabilities, *Eur J Pain* 2016;20:130-7 doi:10.1002/ejp.704.
- 54. Castarlenas E, Jensen MP, von Baeyer CL, et al. Psychometric Properties of the Numerical Rating Scale to Assess Self-Reported Pain Intensity in Children and Adolescents: A Systematic Review, *Clin J Pain* 2017;33:376-83 doi:10.1097/AJP.00000000000406.
- 55. Castarlenas E, Miró J, Sánchez-Rodríguez E. Is the verbal numerical rating scale a valid tool for assessing pain intensity in children below 8 years of age? *J Pain* 2013;14:297-304 doi:10.1016/j.jpain.2012.12.004.
- 56. McKinley S, Coote K, Stein-Parbury J. Development and testing of a Faces Scale for the assessment of anxiety in critically ill patients, *Journal of Advanced Nursing* 2003;41:73-9 doi:10.1046/j.1365-2648.2003.02508.x.
- 57. Spielberger CD, Sydeman SJ. State-trait anxiety inventory and state-trait anger expression inventory. Hillsdale, NJ: Lawrence Erlbaum Associates 1994:292-321.
- 58. Baxter AL, Watcha MF, Baxter WV, et al. Development and validation of a pictorial nausea rating scale for children. *Pediatrics* 2011;127:1542.
- 59. Gold JI, Mahrer NE. Is Virtual Reality Ready for Prime Time in the Medical Space? A Randomized Control Trial of Pediatric Virtual Reality for Acute Procedural Pain Management, *Journal of pediatric psychology* 2018;43 doi:10.1093/jpepsy/jsx129.
- 60. Hoffman HG, Patterson DR, Seibel E, et al. Virtual reality pain control during burn wound debridement in the hydrotank, *The Clinical journal of pain* 2008;24 doi:10.1097/AJP.0b013e318164d2cc.
- 61. ICMJE. International Committee of Medical Journal Editors. 2017. Available: <u>http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html</u> [Accessed 03 Aug 2021].







A randomized controlled trial of virtual reality-based distraction for venipuncture-related distress in children: The VR Study

REB #: Pro00095418	Screening ID	Enrolment Date
PI: Dr. Samina Ali	VR	// <u>2 0</u> dd mmm yyyy

Pre-Screening

Date and Time of Triage	// dd mmm yyyy : (24 hour clock)
Child's Age	years
Child's Sex	Female Male
Was the family approached for this study?	Yes No
If NO, specify reason and STOP HERE.	 Family refused overall consent to be approached for research Legal guardian not present RA busy with another study Did not meet eligibility criteria, specify Other, Specify
If YES, continue to Eligibility.	2



A randomized controlled trial of virtual reality-based distraction for venipuncture-related distress in children:
The VR Study

REB #: Pro00095418	Screening ID	Enrolment Date
PI: Dr. Samina Ali	VR	/ / <u>2 0</u> dd mmm yyyy

Eligibility

Was verbal consent for screening obtained from the fam	ilv?	es 🗌 No

Inclusion Criteria

1. Child aged 6-17 years	🗌 Yes	🗌 No			
2. Requires IV placement	🗌 Yes	🗌 No			
3. Will receive topical anesthetic cream for IV placement	🗌 Yes	🗌 No			
Exclusion Criteria					

Exclusion Criteria

1.	Medically unstable (i.e. CTAS 1, requires immediate IV insertion)	🗌 Yes	🗌 No
2.	Unconscious or not fully alert	🗌 Yes	🗌 No
3.	Visual, auditory or cognitive or mental health issues precluding safe interaction with the VR intervention	🗌 Yes	🗌 No
4.	Conditions that could be exacerbated by the VR environment (as reported by the family) a. <i>current</i> symptomatic nausea / vomiting / dizziness / migraine b. <i>history</i> of psychosis / hallucinations / epilepsy	🗌 Yes	🗌 No
5.	Presence of an infection / injury which could contaminate the VR intervention equipment (as determined by the healthcare team) including but not limited to a. open wounds / infections of the head and neck area b. suspected or confirmed methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) colonization	🗌 Yes	No
6.	Screens positive for 'influenza-like illness' (ILI) as per the current SCH ED screening criteria	🗌 Yes	🗌 No
7.	Child or Parental language barrier precluding the ability to understand and complete study assessments, in the absence of a native language translator	🗌 Yes	🗌 No
8.	Previous enrollment (of child OR parent) in this study	🗌 Yes	🗌 No
ls th	ne family eligible for the study?	🗌 Yes	🗌 No



REB #: Pro00095418	Screening ID	Enrolment Date
PI: Dr. Samina Ali	VR	// <u>2 0</u> dd mmm yyyy
nformed Consent		
	t been obtained from the parent/ legal o	juardian? 🔄 Yes 🛄 I
<u>NO,</u>	<u> </u>	
Specify reason and STOP I	HERE.	 Declined consent Declined assent
		Other, please specify
	R	
<u>YES</u> ,	<u>`</u>	
Specify the date and time o	f Informed Consent	// dd mmm yyyy
		;
		(24 hour clock)
Has a copy of the signed inf	ormed consent been given to the family?	☐ Yes
		□ No; specify:
Has written assent been ob	tained from the child?	Yes
		No; specify:
		No, but verbal assent was obtained and documented
		□ Not required; child < 7y
Has a conv of the signed as	ssent been given to the family?	
		☐ No; specify:
Has written informed conse	nt been provided by the clinical nurse?	
Note: Consent only needs to b entire duration of the study (fo	be provided by the clinical nurse once for the or all 80-90 participants). If consent has not h the clinical nurse, make sure a signed copy	☐ No; specify:
Clinical Nurse Study ID Nur		





A randomized controlled trial of virtual reality-based distraction for venipuncture-related distress in children: The VR Study

REB #: Pro00095418	Screening ID	Enrolment Date
PI: Dr. Samina Ali	VR	/ / <u>2 0</u> dd mmm yyyy

Randomization

If the child satisfies the inclusion/ exclusion criteria and written informed consent has been provided, please RANDOMIZE the participant by clicking on the Randomize button below:

Study Arm	VR InterventionStandard Care



A randomized controlled trial of virtual reality-based distraction for venipuncture-related distress in children: The VR Study

REB #: Pro00095418	Screening ID	Enrolment Date
PI: Dr. Samina Ali	VR	// <u>20</u> ddmmmyyyy

Demographics & History

Demographics

Parent/ Caregiver relationship to child	Mother
	Father
	Other; specify:
Parent / Caregiver Age	years; or 🗌 Prefer not to answer
Parent / Caregiver Sex	E Female
	Male
Parent / Caregiver Highest level of Education	Elementary School
	High School or some High School
	Diploma/ Certificate
	Some Post-Secondary/ University
	University/ Professional Degree
	Decline to answer
First three digits of postal code	(1 st 3 digits ONLY)
Do you identify your child as a member of an ethnic minority?	Yes
	No
· L)
Medical History	

Medical History

Was your child born prematurely?	Yes
	No
If yes, at how many weeks gestation?	weeks
Has your child ever been to the Emergency Department before	☐ Yes
today?	🗌 No
If yes, how many times:	times
Has your child ever been hospitalized?	☐ Yes
	🗌 No
If yes, how many times:	times
Has your child ever had a needle poke in their vein to draw	☐ Yes
blood or put in an intravenous (IV) line?	🗌 No



REB #: Pro00095418	Screening ID			Enrolment Date
PI: Dr. Samina Ali	VR			/ / <u>2 0</u> dd mmm yyyy
If yes, how distressed wa	s your child during the proc	cedure? (if	🗌 1 (no dis	stress at all)
more than one occurrenc	e, ask the parent to recall t	he most	□ 2	
<i>recent event)</i> Choose a r	umber between 1 and 5 th	at best	 □ 3	
describes your child's dis	tress where 1 indicates 'no	distress at		
all' and 5 is 'as distressed	d as possible'			tressed as possible)
Child Experience with Has your child played wit following devices before	h/ used any of the			ablet <i>(to play games)</i>
following devices before	to play games ?	Gaming	console	
		(ex. Xbox	k, Nintendo, P	S4, other)
		☐ Virtual Reality (VR) device		
		(ex. Oculus Quest/ Rift, Samsung Gear VR,		
		HTC Vive, PlayStation VR, other)		
		Robot		
If yes, how frequently?		1		
iPad/ iPod/ iPhone / Tablet:	Gaming console	VR d	evice	Robot
hours/ week	hours/ week	h h	ours/ week	hours/ week
Less than Once per	Less than Once per	Less tha		Less than Once per
week	week	week		week
Less than 5 times in	Less than 5 times in	Less tha	n 5 times in	Less than 5 times in
total	total total			total
Other, specify	Other, specify Other, spe		pecify	Other, specify

VR Study CRF



A randomized controlled trial of virtual reality-based distraction for venipuncture-related distress in children: The VR Study

REB #: Pro00095418	Screening ID	Enrolment Date
PI: Dr. Samina Ali	VR	/ / <u>2 0</u> ddmmmyyyy


PRE-Procedure: Child Scores

NOTE: Begin the video recorder (iPad) approximately 5 minutes before the start of the IV procedure, and stop the recording 5 minutes after the end of the procedure.

Baseline Scores: Child

Heart Rate (record from Triage)	bpr	n	
Time pre-procedure scores collected	dd	/ mmm : ur clock)	/
Pain Score: verbal Numerical Rating Scale (vNRS) "On a scale of 0 to 10, where 0 is no pain and 10 is the worst pain you can imagine, what is your pain level now?"	/ 10	,	
Distress Score: Numerical Rating Scale "On a scale of 0 to 10, where 0 is no distress and 10 is the most distress you can imagine having, what is your distress level now?"	/ 10	D	

"These faces are showing different amounts of being scared. This face [point to the left-most face] is not scared at all, this face is a little bit more scared [point to the second face from left], a bit more scared [sweep finger along scale], right up to the most scared possible [pint to the last face on the right]. Have a look at these faces and choose the one that shows how scared you are right now."







A randomized controlled trial of virtual reality-based distraction for venipuncture-related distress in children: The VR Study

REB #: Pro00095418	Screening ID	Enrolment Date
PI: Dr. Samina Ali	VR	/ / <u>2 0</u> dd mmm yyyy

PRE-Procedure: Parent / Caregiver STAI Questionnaire

We would ask that you complete the following questions as they relate to your feelings about your child's upcoming IV procedure, today. A number of statements which people have used to describe themselves are given below. Read each statement and then circle the appropriate number to indicate how you feel right now, that is, at this moment. There are no right or wrong answers. Do not spend too much time on any one statement but give the answer which seems to describe your feelings best.

18						
19		14				
20		Not at all Somewhat Moderately so Very much so				
21						
22 23	1.	I feel calm	1	2	3	4
24 25	2.	I feel secure	1	2	3	4
25 26	3.	I am tense	1	2	3	4
27 28	4.	I feel strained	1	2	3	4
29	5.	I feel at ease	1	2	3	4
30 31	6.	I feel upset	1	2	3	4
32 33	7.	I am presently worrying over possible misfortunes	1	2	3	4
34	8.	I feel satisfied	1	2	3	4
35 36	9.	I feel frightened	1	2	3	4
37 38	10.	I feel comfortable	1	2	3	4
39	11.	I feel self-confident	1	2	3	4
40 41	12.	I feel nervous	1	2	3	4
42 43	13.	I am jittery	1	2	3	4
43 44	14.	I feel indecisive	1	2	3	4
45 46	15.	I am relaxed	1	2	3	4
47 48	16.	I feel content	1	2	3	4
48 49	17.	I am worried	1	2	3	4
50 51	18.	I feel confused	1	2	3	4
52	19.	I feel steady	1	2	3	4
53 54	20.	I feel pleasant	1	2	3	4
55						



A randomized controlled trial of virtual reality-based distraction for venipuncture-related distress in children: The VR Study

REB #: Pro00095418	Screening ID	Enrolment Date
PI: Dr. Samina Ali	VR	// <u>20</u> ddmmmyyyy

DURING-Procedure

- Start the iPad video recording approximately 5 minutes prior to the start of the procedure.
- For children randomized to the VR group: Immediately after PRE-procedure scores and STAI are completed, research assistant will set up the VR equipment.
- The staff ED nurse will then begin the IV set-up

Start time of IV procedure:		_/	_/
(Defined as the time the staff nurse begins to clean the IV site)	dd	mmm	уууу
\mathbf{O}	(24 h	_: our clock)	
End time of IV procedure/ attempt:	,	,	
(Defined as the last point of contact by the staff nurse (ex. taping cannula in place with or without arm board, wrapping arm with gauze and taping the gauze in place)	dd	_/ mmm :	/ уууу
	(24 h	our clock)	

Position of Child during IV attempt:	Sitting up Lying down (supine)		
Location of first IV attempt:	 Antecubital Fossa – RIGHT Antecubital Fossa – RIGHT Dorsum hand – RIGHT Dorsum hand – LEFT Other, specify 		
Was the first IV placement attempt successful?			
 If NO, how many attempts, in total, were made for the IV during this 'episode'? 	attempts		
Was an IV successfully placed during this 'episode'?	Yes No		

Any adverse events or side effects?	Yes No
Do not suggest any AEs to the participant; Instead, ask more general questions such as "how are you feeling?" or "are you having any side effects?" or "are you feeling any different than before?", and let the child answer spontaneously.	If " YES ", complete a separate entry for each AE on the AE Form



REB #: Pro00095418		Screening ID		Enrolment Date
PI: Dr. Samina Ali	VR			// <u>2</u> 0/ dd mmm yyyy
IMEDIATELY PO OTE: Post-procedure so ocedure is complete:	cores/ questionnair		-	<u>possible</u> after the
ost-procedure Score	es: Child			
Time post-procedure sc	ores collected			dd mmm yyyy
	0			:: (24 hour clock)
Pain Score: verbal Num 'On a scale of 0 to 10, v magine, what was your	where 0 is no pain a	and 10 is the wors	t pain you can	/ 10
Distress Score: Numerie "On a scale of 0 to 10, v you can imagine having <u>IV poke</u> "	where 0 is no distre	ess and 10 is the r		/ 10
scared at all, this face is [sweep finger along sca	ng different amoun s a little bit more sc le], right up to the r	ts of being scared ared [point to the most scared possi	second face from ole [pint to the la	to the left-most face] is not in left], a bit more scared ist face on the right]. Have ing the needle / IV poke."
call that feeling of being all, who feel a little bit n	felt like you were g sick to the stomac auseated, who feel ble to feel." [Point to	joing to throw up b h nausea. These even more nause	efore? How did aces show child ated, and these	your tummy feel then? We ren who feel no nausea at are children who have the .] "Which face is more like



REB #: Pro00095418	Screening ID	Enrolment Date
PI: Dr. Samina Ali	VR	/ / <u>2 0</u> dd mmmyyyy
· · · · · ·	vere you with the IV start today, on a scale of 1 at all happy" and 5 means "Very happy"?	to 5, 1 "Not at all happy 2 3 4 5 "Very happy"
	where 1 means "Not at all happy" and 5 means appy were you <u>with the pain treatment</u> for your I	 ✓ 1 "Not at all happy" ✓ 2 ✓ 3 ✓ 4 ✓ 5 "Very happy"
Did the [distraction / t	toys / VR goggles] help you today?	Yes, it helped No, it didn't help 'm not sure
	t an IV or needle poke again, would you want to / toys / VR goggles] again?	use Yes, I would No, I wouldn't I'm not sure
Con you toll n	ne why/ why not?	

As soon as possible after completion of procedure, research assistant to give:

1. Post-Procedure Parent STAI and Satisfaction Questionnaire to parent/ caregiver

2. Nurse Satisfaction Questionnaire to staff ED nurse





 A randomized controlled trial of virtual reality-based distraction for venipuncture-related distress in children: The VP Study

REB #: Pro00095418	Screening ID	Enrolment Date
PI: Dr. Samina Ali	VR	/ / <u>2 0</u> dd mmm yyyy

POST-Procedure: Parent / Caregiver STAI Questionnaire

We would ask that you complete the following questions as they relate to your feelings about your child's IV procedure that just happened. A number of statements which people have used to describe themselves are given below. Read each statement and then circle the appropriate number to indicate how you feel right now, that is, at this moment. There are no right or wrong answers. Do not spend too much time on any one statement but give the answer which seems to describe your feelings best.

10		13				
19 20		I4 Not at all Somewhat Moderately so Very much so				
20						
22 23	1.	I feel calm	1	2	3	4
24	2.	I feel secure	1	2	3	4
25 26	3.	I am tense	1	2	3	4
27 28	4.	I feel strained	1	2	3	4
29 30	5.	I feel at ease	1	2	3	4
31	6.	I feel upset	1	2	3	4
32 33	7.	I am presently worrying over possible misfortunes	1	2	3	4
34 35	8.	I feel satisfied	1	2	3	4
36	9.	I feel frightened	1	2	3	4
37 38	10.	I feel comfortable	1	2	3	4
39 40	11.	I feel self-confident	1	2	3	4
41	12.	I feel nervous	1	2	3	4
42 43	13.	I am jittery	1	2	3	4
44 45	14.	I feel indecisive	1	2	3	4
46	15.	I am relaxed	1	2	3	4
47 48	16.	I feel content	1	2	3	4
49 50	17.	I am worried	1	2	3	4
51	18.	I feel confused	1	2	3	4
52 53	19.	I feel steady	1	2	3	4
54 55	20.	I feel pleasant	1	2	3	4



REB #: Pro00095418		Screening ID		Enrolment Date	
PI: Dr. Samina Ali	Dr. Samina Ali VR		-	// <u>2</u> 0 dd mmm yy	
OST-Procedure	: Caregiver Sat	isfaction Que	stionnaire		
) Please rate your o	overall satisfaction	with your child's	IV start:		
Very				Very	
Dissatisfied 1	Dissatisfied 2	Neutral 3	Satisfied 4	Satisfied 5	
	Ġ				
Please Explain:					
	0				
) Please rate your s	satisfaction with the	e management of	your child's pain	for their IV start:	
Very				Very	
Dissatisfied	Dissatisfied	Neutral	Satisfied	Satisfied	
1 □	2	3	4	5 □	
Please Explain:		0			
			1		
			0		
) Would you use th future?	e same methods to	manage your chi	ld's pain from nee	edle pokes in the	
└ Yes │ No					
Why / Why not?					
	Thank you for you it is	Ir participation in very much appre		ly,	
VR Study CRE	,	Version July 15 20	20	Page 13 of 7	



REB #: Pro00095418		Screening ID		Enrolment Date
PI: Dr. Samina Ali	VR			// <u>2 0</u> ddmmyy
lurse Satisfactio	on Questionnair	e (VR Group)		
1) Overall, how easy	or difficult was it to pe	erform the IV inse	tion for this child?	
Very Easy 1	Easy 2	Neutral 3	Difficult	Very Difficult 5
2) Please rate your s	atisfaction with this ch	hild's IV start:		
Very Dissatisfied 1	Dissatisfied	Neutral 3	Satisfied 4	Very Satisfied 5
 Would you use the from IV insertion in Yes No 	n the future?	CZ.	•	
 Could you please 	rate the following on a	a scale of 1-5, whe	ere 1= Not at all ar	
	action with the Virtual o use the VR device to n the future	,	_	$\begin{array}{cccccccccccccccccccccccccccccccccccc$
The degree to white The degree to white	ch the VR device implich the VR improved y ch the VR improved y ch the VR disrupted y	your ability to inse	rt the IV	
5) Did the VR device Yes (approx No	that was used during imately how much tim	•		•
 Is there anything e for a child using a 	else that you would lik VR device?	e to tell us, today,	about your experi	ence inserting an IV



A randomized controlled trial of virtual reality-based distraction for venipuncture-related distress in children: The VR Study				
REB #: Pro00095418	Screening ID	Enrolment Date		
PI: Dr. Samina Ali	VR	// <u>2 0</u> dd mmm y		
7) How many years	of practice do you have as a nurse (all settings)?	N/A		
8) How many years	of practice do you have as a nurse in the ED?	_		
9) Please indicate th	e amount of time spent in the pediatric emergency dep	partment (PED):		
0.25% of r	ny time is spent in the pediatric ED			
	my time is spent in the pediatric ED			
	my time is spent in the pediatric ED			
☐ 76-100% c	of my time is spent in the pediatric ED			
	Thank You!!			
	Version July 15, 2020	Dago 1E of 1		



			Screening ID		Enrolment	Date
PI:	Dr. Samina Ali	VR		-	// dd/	<u>20</u> уу
Nu	urse Satisfact	tion Questionnai	re (Standard	Care Group)		
1)	Overall, how easy	or difficult was it to pe	erform the IV inser	tion for this child?	,	
	Very Easy 1	Easy 2	Neutral 3	Difficult 4	Very Difficult 5	
2)	Please rate your s	satisfaction with this ch	nild's IV start:			
	Very Dissatisfied 1	Dissatisfied 2	Neutral	Satisfied 4	Very Satisfied 5	
-	another child's pa	e same methods (ie. S in and distress from IV	/ insertion in the fu	uture?		
4)	Could you please	rate the following on a	a scale of 1-5, whe	ere 1= Not at all ar		_
	Your overall satisf	action with the pain m	anagement plan to	1 odav		5 □
•	Your willingness to	o use a similar pain ma pain and distress in th	anagement plan to			
	The degree to whi experience	ch the pain managem	ent plan improved	the child's		
	The degree to whi to insert the IV	ch the pain managem	ent plan improved	d your ability		
	The degree to whi to insert the IV	ch the pain managem	ent plan disrupte	d your ability		
	the time required	of Care pain managen to insert the IV? kimately how much tim	-			e
	Is there anything	else that you would lik Standard of Care pair		• •	ience inserting an	IV



		The VR Study	
REB #: Pro000954	118	Screening ID	Enrolment Dat
PI: Dr. Samina Al		VR	// 2 (dd/ 2 (
7) How many y	ears of practice d	o you have as a nurse (all settings)?	N/A
8) How many y	ears of practice d	o you have as a nurse in the ED?	N/A
9) Please indic	ate the amount of	time spent in the pediatric emergency de	epartment (PED):
	% of my time is so	ent in the pediatric ED	
		pent in the pediatric ED	
		spent in the pediatric ED	
	•		
/0-1	Ju 76 of my time is	spent in the pediatric ED	
	ifu vour position if	other than attending ED nurse (e.g., IV I	auroo attanding CD
, .		or nurse from other service [specify], etc	
priysician, re	sident, physician	of hurse from other service [specify], etc)•
		Thank You!!	
VR Study C	DC	Version July 15, 2020	Page 17 of



REB #: Pro00095418	Screening	ID		Enrolment Da
PI: Dr. Samina Ali	VR			// 2
)ischarge Informatio	'n			
Disposition		Disch	narged Ho	ome
			<u> </u>	/
Date & Time of Discharge f	rom the ED	dd	mmm :	уууу
		(24 ho	ur clock)	-
Length of Stay in ED (calcu	llated field):		urs	
Discharge Diagnosis				



REB #: Pro00095418	Screening ID	Enrolment Date
PI: Dr. Samina Ali	VR	// 2 0/ 2 0/ dd / yyy
RA Satisfaction (Questionnaire (For Standard Care group, ans	wer Q6 ONLY)
) Could you please ra	te the following on a scale of 1-5, where 1= Not at all	and 5=Very much
Marina and a state		1 2 3 4 5
	action with the Virtual Reality (VR) device today	
Ease of set-up of the Your satisfaction we device	rith the amount of time it took to set up the VR	
	k with the VR device again	
	much time was needed to set up the VR device with t and questionnaire time)	he child, today?
minutes		
Controller Headphone 4) Were the VR Goggle	es es / Headset kept on for the entire duration of the proc	cedure?
5) What applications /	game(s) did the child play during the procedure?	
Check all that apply. I	et / Smartphone	
, .	chnical or other issues with operating / handing the V	• •
 Is there anything els 	e that you would like to tell us about your experience v	vith the VR googles today?
VR Study CRF	Version July 15, 2020	Page 19 of 21



A randomized controlled trial of virtual reality-based distraction for venipuncture-related distress in children:

The	VR	Stu	dy
-----	----	-----	----

REB #: Pro00095418	Screening ID	Enrolment Date
PI: Dr. Samina Ali	VR	/ / <u>2 0</u> dd mmm yyyy

Adverse Events Log

	To be filled out by Research Assistant						o be filled out	by Site Investig	ator	
No.	Description of Adverse Event	Onset Date & Time (dd/mmm/ yyyy HH:MM)	Action Taken 1.None 2.Medication 3.New or Prolonged Hospitalization 4.Procedure / Surgery 5.Other, specify	Outcome 1.Resolved 2.Resolved with Sequelae 3.Resolving 4.Unresolved 5.Fatal 6.Lost to follow-up	Date & Time Resolved (dd/mmm/ yyyy HH:MM)	Intensity grade: 1. Mild 2. Moderate 3. Severe	Expected AE? Y / N	Relationship to Study 1.Unrelated 2.Unlikely 3.Possible 4.Probable 5.Definite	SAE? Y/N	Site PI Initial
1				191	ien					
2						0 7j				
3										



A randomized controlled trial of virtual reality-based distraction for venipuncture-related distress in children: The VR Study

REB #: Pro00095418	Screening ID	Enrolment Date
PI: Dr. Samina Ali	VR	/ / <u>2 0</u> dd mmm yyyy

Early Withdrawal

ONLY fill out this form in the event of an early withdrawal

Date of Discontinuation:	// dd mmm yyyy
Reasons for Discontinuation: (check all that apply)	 Adverse Event / Serious Adverse Event Death Withdrawal of Consent / Assent Protocol Violation, Specify Other, Specify
If withdrew consent / assent:1. Permission to use collected data?2. Permission to conduct Chart Review?	☐ Yes ☐ No ☐ Yes ☐ No
Comments:	
	4

Reporting checklist for protocol of a clinical trial.

7 8 9			Reporting Item	Page Number
9 10 11 12 13 14	Title	<u>#1</u>	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
15 16 17 18	Trial registration	<u>#2a</u>	Trial identifier and registry name. If not yet registered, name of intended registry	1
19 20	Trial registration:	<u>#2b</u>	All items from the World Health Organization	5-7 (Table 1)
21 22	data set		Trial Registration Data Set	
23 24	Protocol version	<u>#3</u>	Date and version identifier	2
25 26 27 28	Funding	<u>#4</u>	Sources and types of financial, material, and other support	14
28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50	Roles and responsibilities: contributorship	<u>#5a</u>	Names, affiliations, and roles of protocol contributors	15
	Roles and responsibilities: sponsor contact information	<u>#5b</u>	Name and contact information for the trial sponsor	5
	Roles and responsibilities: sponsor and funder	<u>#5c</u>	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	14
50 51 52 53 54 55 56 57 58	Roles and responsibilities: committees	<u>#5d</u>	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or	N/A
59 60		For peer	review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

		BMJ Open	Page 48 of 5
		groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	
Background and rationale	<u>#6a</u>	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	4-5
Background and rationale: choice of comparators	<u>#6b</u>	Explanation for choice of comparators	7-8
Objectives	<u>#7</u>	Specific objectives or hypotheses	5
Trial design	<u>#8</u>	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, non-inferiority, exploratory)	5
Study setting	<u>#9</u>	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	7
Eligibility criteria	<u>#10</u>	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	7
Interventions: description	<u>#11a</u>	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	7-8
Interventions: modifications	<u>#11b</u>	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving / worsening disease)	9,13
	For peer	review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

Interventions: adherance	<u>#11c</u>	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return; laboratory tests)	9
Interventions: concomitant care	<u>#11d</u>	Relevant concomitant care and interventions that are permitted or prohibited during the trial	8
Outcomes	<u>#12</u>	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	10-11
Participant timeline	<u>#13</u>	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	8-9 and Figure 3
Sample size	<u>#14</u>	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	11
Recruitment	<u>#15</u>	Strategies for achieving adequate participant enrolment to reach target sample size	11
Allocation: sequence generation	<u>#16a</u> For peer	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	8
	adherance Interventions: concomitant care Outcomes Participant timeline Sample size Recruitment Allocation: sequence	adherance #11d Concomitant care #112 Outcomes #12 Participant timeline #13 Sample size #14 Recruitment #15 Allocation: sequence #16a	adheranceprotocols, and any procedures for monitoring adherence (eg, drug tablet return; laboratory tests)Interventions:#11dRelevant concomitant care and interventions that are permitted or prohibited during the trialOutcomes#12Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, ehange from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommendedParticipant timeline#13Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)Sample size#14Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculationsAllocation: sequence generation#16aMethod of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or

Page 50 of 53

1 2 3 4 5 6 7 8	Allocation concealment mechanism	<u>#16b</u>	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	8
9 10 11 12 13	Allocation: implementation	<u>#16c</u>	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	8
14 15 16 17 18 19 20	Blinding (masking)	<u>#17a</u>	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	8
21 22 23 24 25 26 27	Blinding (masking): emergency unblinding	<u>#17b</u>	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	N/A
27 28 29 30 31 32 33 34 35 36 37 38 39 40 41	Data collection plan	<u>#18a</u>	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	8-9 and Appendix 2 for Case Report Form
42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59	Data collection plan: retention	<u>#18b</u>	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	9
60		For peer	review only - http://bmjopen.bmj.com/site/about/guidelines.>	ntml

Page 51 of 53

1 2 3 4 5 6 7 8 9 10 11	Data management	<u>#19</u>	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	12
12 13 14 15 16 17 18	Statistics: outcomes	<u>#20a</u>	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	11
19 20 21 22	Statistics: additional analyses	<u>#20b</u>	Methods for any additional analyses (eg, subgroup and adjusted analyses)	11
23 24 25 26 27 28 29	Statistics: analysis population and missing data	<u>#20c</u>	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	11
30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49	Data monitoring: formal committee	<u>#21a</u>	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	N/A
	Data monitoring: interim analysis	<u>#21b</u>	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	N/A
50 51 52 53 54 55 56 57 58 59	Harms	<u>#22</u>	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	11
60		For peer	review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

BMJ Open
Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor
Plans for seeking research ethics committee / institutional review board (REC / IRB) approval

- Protocol
 #25
 Plans for communicating important protocol

 amendments
 modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC / IRBs, trial participants, trial registries, journals, regulators)
- Consent or assent#26aWho will obtain informed consent or assent from
potential trial participants or authorised
surrogates, and how (see Item 32)Consent or assent:#26bAdditional consent provisions for collection and

use of participant data and biological specimens

- Confidentiality#27How personal information about potential and
enrolled participants will be collected, shared,
and maintained in order to protect confidentiality
before, during, and after the trial12Declaration of
interests#28Financial and other competing interests for
principal investigators for the overall trial and
each study site13
 - Data access
 #29
 Statement of who will have access to the final
 Table 1

 trial dataset, and disclosure of contractual agreements that limit such access for investigators
 Table 1
- Ancillary and post#30Provisions, if any, for ancillary and post-trialN/Atrial carecare, and for compensation to those who suffer
harm from trial participationN/ADissemination#31aPlans for investigators and sponsor to13
- 54Dissemination#31aPlans for investigators and sponsor to55policy: trial resultscommunicate trial results to participants,
healthcare professionals, the public, and other58relevant groups (eg, via publication, reporting in
For peer review only http://bmjopen.bmj.com/site/about/guidelines.xhtml

N/A

14-15

12-13

N/A

Auditing

approval

Research ethics

ancillary studies

60

	results databases, or other data sharing arrangements), including any publication restrictions	
3Dissemination policy: authorship	#31b Authorship eligibility guidelines and any intended use of professional writers	15-16
Dissemination policy: reproducible research	#31c Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	Table 1
Informed consent materials	#32 Model consent form and other related documentation given to participants and authorised surrogates	Appendix 1
Biological specimens	 #33 Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable 	N/A
<u>Network</u> in collaboration		

BMJ Open

BMJ Open

A study protocol for a randomized controlled trial of virtual reality-based distraction for intravenous insertion-related distress in children

Journal:	BMJ Open
Manuscript ID	bmjopen-2021-057892.R1
Article Type:	Protocol
Date Submitted by the Author:	12-Feb-2022
Complete List of Authors:	Ali, Samina; University of Alberta, Pediatrics Rajagopal, Manasi; University of Alberta, Pediatrics Stinson, Jennifer; Toronto SickKids Ma, Keon; University of Calgary Cumming School of Medicine, Pediatrics Vandermeer, Ben; University of Alberta, Pediatrics Felkar, Bailey; London Health Sciences Centre, Pediatrics Schreiner, Kurt; University of Alberta, Pediatric Parents' Advisory Group Proctor, Amanda; Alberta Health Services Plume, Jennifer; Alberta Health Services Hartling, Lisa; University of Alberta, Pediatrics
Primary Subject Heading :	Paediatrics
Secondary Subject Heading:	Anaesthesia
Keywords:	ACCIDENT & EMERGENCY MEDICINE, Pain management < ANAESTHETICS, Paediatric A&E and ambulatory care < PAEDIATRICS, PAIN MANAGEMENT

SCHOLARONE[™] Manuscripts

Title: A study protocol for a randomized controlled trial of virtual reality-based distraction for intravenous insertion-related distress in children Lay Title: Virtual Reality Based Distraction for Painful Procedures in Children Authorship: Samina Ali MDCM^{1,2,*}, Manasi Rajagopal MBT¹, Jennifer Stinson³, Keon Ma MD⁴, Ben Vandermeer MSc⁵, Bailey Felkar MS CCLS⁶, Kurt Schreiner MPM⁷, Amanda Proctor⁸, Jennifer Plume BM, MA MTA⁹, Lisa Hartling PhD^{1,5} 1 Department of Pediatrics, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Alberta, Canada 2 Women & Children's Health Research Institute, University of Alberta, Edmonton, Alberta, Canada 3 Child Health Evaluative Sciences, Research Institute, The Hospital for Sick Children and the Lawrence S. Bloomberg Faculty of Nursing, University of Toronto, Toronto, Ontario, Canada 4 Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada 5 Alberta Research Centre for Health Evidence, Department of Pediatrics, University of Alberta, Edmonton, Alberta, Canada 6 London Health Sciences Centre Children's Hospital, London, Ontario, Canada 7 Pediatric Parents' Advisory Group, University of Alberta, Edmonton, Canada 8 Stollery Youth Advisory Council and Patient and Family Centred Care, Edmonton, Alberta, Canada 9 Stollery Children's Hospital, Edmonton, Alberta, Canada *denotes corresponding author, and contact for public and scientific inquiries 3-583 Edmonton Clinic Health Academy 11405 - 87 Avenue Edmonton, AB T6G 1C9 Phone: (780) 248-5574 Fax: (888) 775-8876 Email: sali@ualberta.ca Keywords: virtual reality, distress, pain, distraction, pediatrics, intravenous Trial Protocol Version 15 July 2020 Trial Registration: clinicaltrials.gov NCT04291404 WHO Trial Registration Data Set: See Table 1 Word Count: 3963/4000 words For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

The Virtual Reality Study Protocol Version 1.0

Ali S, Rajagopal M, et al

ABSTRACT

Introduction. Intravenous (IV) insertions are among the most performed procedures for children seeking medical care; they are often a painful and stressful experience for both children and their caregivers. Pediatric distress and pain that is inadequately treated may lead to a frightened and uncooperative child, repeated IV attempts and overall frustration with care for both the family and clinical team. We hypothesize that distraction via an immersive virtual reality (VR) experience may reduce the associated distress for children undergoing IV insertions.

Methods and analysis.

This two-armed randomized controlled superiority trial will be conducted in a Canadian pediatric emergency department and will aim to enroll 80 children overall. Children will be randomized to receive either departmental standard of care alone or standard of care plus an immersive VR experience. Children 6 to 17 years of age who are undergoing IV insertion and have topical anesthetic application will be considered for inclusion. Our primary objective is to compare the reduction of distress between the two study arms. The primary outcome will be the child's observed distress score as measured by the Observational Signs of Behavioral Distress-Revised (OSBD-R) tool. Secondary outcomes include the child's pain intensity and fear, parental anxiety, satisfaction with the IV procedure, as well as adverse events. Recruitment launched in September 2020 and is expected to end in March 2022.

Ethics and dissemination. This study has been approved by the Health Research Ethics Board (University of Alberta). Informed consent will be obtained from parents or guardians, and assent from children. Study data will be submitted for publication irrespective of results. This study is funded through a Women and Children's Health Research Institute Innovation grant. Purchase of the VR equipment was facilitated through a Stollery Children's Hospital Foundation small equipment grant.

Trial registration number: NCT04291404, First registered March 02, 2020

Words: 299/ 300

Article Summary Strengths and limitations of this study

- 1. This randomized controlled trial will assess the effectiveness of immersive virtual reality-based distraction for the reduction of IV insertion-related distress in children.
- 2. This study measures patient- and family-relevant outcomes including child distress, pain, fear, and safety as well as parental anxiety and satisfaction.
- 3. The study team includes parent and patient partners as co-investigators who will inform study methods and outcomes.
- 4. The study intervention will be compared to current standard of care; however, since there is no consistent standard of care distraction practice, this may create some heterogeneity in the comparison arm of the study.
- 5. Given the nature of the study intervention, it is not possible to blind patients, parents/caregivers, health care providers, or outcome assessors; the statistician will be blinded to study arms.

The Virtual Reality Study Protocol Version 1.0

INTRODUCTION

Needle procedures, including venipuncture and intravenous (IV) placement, are described by children as some of the most distressing and painful parts of their healthcare visit. [1-4] Untreated distress and pain can lead to a scared and uncooperative child, a need for repeated IV attempts, reduced efficiency and overall dissatisfaction with care for the patient, family and the health care team. [3, 5, 6] Unpleasant medical encounters in childhood can also shape an individual's perception of healthcare and expectations of pain in adulthood. [7-9] This can result in increased anticipatory anxiety and pain for future medical procedures or an avoidance of healthcare services, altogether. [1] As needle procedures form a routine and necessary part of care in the emergency department (ED), it is an important responsibility of health care providers to adequately manage children's distress and pain, wherever possible.[10,11]

The recommended and responsible approach to managing children's procedural pain incorporates physical, psychological, and pharmacological components. [10-15] While pharmacological interventions such as topical anesthetic creams are available, their effectiveness is limited to *pain*, as they do not address procedure-related *distress and* anxiety. [10] Distraction therapy is a commonly employed psychological strategy which involves engaging children in a cognitive task or activity to divert attention away from nociceptive stimuli. [16] An effective distractor provides sensory stimulation and is highly engaging and age-appropriate to fully capture the attention of a child. [12,16] Previous research has indicated that children who use distraction as an active form of coping experience reduced pain and distress during painful procedures. [12, 17, 18] Traditional distraction techniques such as music, video, stories, imagery, and focused breathing have been previously explored for children undergoing unpleasant medical procedures and demonstrated mixed results. [19-24] Our team's recently conducted systematic review of digital technologies has suggested that digital distraction techniques appear promising, but require further study to confirm their utility for painful procedures. [25]

Virtual Reality (VR) technology is rapidly emerging as a novel distraction tool for children undergoing various medical procedures. Unlike traditional distraction techniques, VR uses a combination of visual, auditory, and tactile stimuli to create the illusion of being fully immersed in an artificial three-dimensional environment. [26] A Head Mounted Display (or 'VR goggles') delivers the VR video and audio to the child, and serves to block out the view and sounds of the hospital room. [14] This further removes the patient from the chaos of the treatment room and diverts their attention away from surrounding painful and anxiety-evoking stimuli. To date, VR distraction therapy has shown promise for patients undergoing a range of distressing healthcare procedures, including burn wound cleaning, chest radiography, dental interventions, and chemotherapy. [27-32] Therapeutic VR has also led to improved health outcomes for patients with anxiety disorders, phobias, post-traumatic stress disorder, and eating disorders. [33-36]

The Virtual Reality Study Protocol Version 1.0

The ED presents unique challenges when attempting to distract a child during a painful medical procedure. Due to the chaotic, noisy, and unpredictable environment, it is an ideal place to 'stress-test' the ability of VR technology to immerse a child into a distracting and 'safe' space. Rapid advances in VR technology over the last few years, and improved cost-effectiveness, offers a unique opportunity to explore its use in the ED setting. A few recently published studies from the pediatric ED setting suggest that VR has a positive impact on IV insertion-related pain and satisfaction, [12, 14, 37-40] although outcomes such as distress and adverse effects remain poorly studied. [38] Recent systematic reviews, which have mostly focused on non-ED and in-patient settings, have shown that the current evidence is inconclusive, sometimes contradictory, and have called for further research in larger study groups. [41-42] Furthermore many previous trials utilize proprietary software designed specifically for medical use which may limit widespread accessibility to all centers. This study will evaluate an "off-the-shelf" device with a range of widely accessible software.

This study will evaluate the effectiveness of a VR intervention in reducing IV placementrelated distress for children 6-17 years old presenting to the ED. We hypothesize that the use of immersive VR distraction will reduce children's IV related distress when compared with standard of care and will improve overall satisfaction with the procedure for the patient, family, and the health care team.

METHODS AND ANALYSIS

This study is a two-armed, randomized, controlled superiority trial. The study protocol is reported using the SPIRIT-PRO reporting guidelines. [43] (See Table 1.)

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Table 1. WHO Trial Registration Data Set

Data Category	Information
Primary Registry and Trial	clinicaltrials.gov NCT04291404
Identifying Number	
Date of Registration in	March 2, 2020
Primary Registry	
Secondary Identifying	University of Alberta Research Ethics Board #
Numbers	Pro00095418
Source(s) of Monetary or	Stollery Children's Hospital Foundation and the
Material Support	Women and Children Health Research Institute
	Innovation Grant
Primary Sponsor	University of Alberta
Secondary Sponsor(s)	-
Contact for Public Queries	Dr. Samina Ali 780.248.5575 sali@ualberta.ca
Contact for Scientific Queries	Dr. Samina Ali 780.248.5575 sali@ualberta.ca
Public Title	The Virtual Reality Trial
Scientific Title	A randomized controlled trial of virtual reality-based
	distraction for intravenous insertion-related distress in
	children
Countries of Recruitment	Canada
Health Condition(s) or	Intravenous insertion-related distress
Problem(s) Studied	
Intervention(s)	Addition of distraction via an immersive virtual reality
	experience to departmental standard of care during the
	intravenous (IV) insertion procedure
Key Inclusion and Exclusion	To be eligible to participate in this study, an individual
Criteria	must meet all of the following inclusion criteria: (a)
	child aged 6–17 years; (b) requires IV placement; and
	(c) will receive topical anesthetic cream for IV
	placement. Children meeting any of the following
	criteria will be excluded: (a) medically unstable; (b)
	unconscious or not fully alert; (c) visual, auditory
	cognitive, or mental health issues precluding safe
	interaction with the VR intervention; (d) conditions
	that could be exacerbated by the VR environment,
	such as <i>current</i> symptomatic nausea / vomiting /
	dizziness/migraine, or a <i>history</i> of
	psychosis/hallucinations/epilepsy; (e) presence of an
	infection/injury which could contaminate the VR
	intervention equipment such as open wounds/
	infections of the head and neck area, or

The Virtual Reality Study Protocol Version 1.0

1	
2	
3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
40 47	
47	
40 49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	

positive for 'influenza-like illness' as per departmental screening criteria; (g) language barrier precluding the ability to understand and complete study assessments, in the absence of a native language translator; or (h) previous enrollment in this study.Study TypeRandomized Controlled Superiority TrialDate of First EnrollmentOctober 5, 2020Sample Size80Recruitment StatusActively recruitingPrimary Outcome(s)The primary outcome will be the child's total observed distress score during the IV procedure as measured on the Observational Signs of Behavioral Distress- Revised (OSBD-R) tool.Key Secondary OutcomesSecondary outcomes include: (a) the child's self- reported pain score during the IV procedure, using an 11-point 0-10 verbal Numerical Rating Scale (vNRS); (b) the child's self-reported fear score during the IV insertion as measured by the Children's Fear Scale (CFS); (c) parental/caregiver anxiety associated with the procedure, as assessed by the State Trait Anxiety Inventory - State Trait Revised Version (STAL-S, Form Y); (d) satisfaction with the procedure inserting the IV, as assessed by a 5-point Likert scale; and (e) the proportion of children who experience adverse events related to the study intervention.Ethics ReviewUniversity of Alberta Research Ethics Board # Pro00095418Completion date-Summary Results-IPD sharing statementDe-identified data can be shared, on a case-by-case		<i>Staphylococcus aureus</i> colonization; (f) screens
screening criteria; (g) language barrier precluding the ability to understand and complete study assessments, in the absence of a native language translator; or (h) previous enrollment in this study.Study TypeRandomized Controlled Superiority TrialDate of First EnrollmentOctober 5, 2020Sample Size80Recruitment StatusActively recruitingPrimary Outcome(s)The primary outcome will be the child's total observed distress score during the IV procedure as measured on the Observational Signs of Behavioral Distress- Revised (OSBD-R) tool.Key Secondary OutcomesSecondary outcomes include: (a) the child's self- reported pain score during the IV procedure, using an 11-point 0-10 verbal Numerical Rating Scale (vNRS); (b) the child's self-reported fear score during the IV insertion as measured by the Children's Fear Scale (CFS); (c) parental/caregiver anxiety associated with the procedure, as assessed by the State Trait Anxiety Inventory - State Trait Revised Version (STAI-S, Form Y); (d) satisfaction with the procedure for the child, their parent/caregiver and the nurse inserting the IV, as assessed by a 5-point Likert scale; and (e) the proportion of children who experience adverse events related to the study intervention.Ethics ReviewUniversity of Alberta Research Ethics Board # Pro00095418Completion date-Summary Results-IPD sharing statementDe-identified data can be shared, on a case-by-case		1.0
ability to understand and complete study assessments, in the absence of a native language translator; or (h) previous enrollment in this study.Study TypeRandomized Controlled Superiority TrialDate of First EnrollmentOctober 5, 2020Sample Size80Recruitment StatusActively recruitingPrimary Outcome(s)The primary outcome will be the child's total observed distress score during the IV procedure as measured on the Observational Signs of Behavioral Distress- Revised (OSBD-R) tool.Key Secondary OutcomesSecondary outcomes include: (a) the child's self- reported pain score during the IV procedure, using an 11-point 0-10 verbal Numerical Rating Scale (vNRS); (b) the child's self-reported fear score during the IV insertion as measured by the Children's Fear Scale (CFS); (c) parental/caregiver anxiety associated with the procedure, as assessed by the State Trait Anxiety Inventory - State Trait Revised Version (STAI-S, Form Y); (d) satisfaction with the procedure for the child, their parent/caregiver and the nurse inserting the IV, as assessed by a 5-point Likert scale; and (e) the proportion of children who experience adverse events related to the study intervention.Ethics ReviewUniversity of Alberta Research Ethics Board # Pro00095418Completion date-PD sharing statementDe-identified data can be shared, on a case-by-case		
in the absence of a native language translator; or (h) previous enrollment in this study.Study TypeRandomized Controlled Superiority TrialDate of First EnrollmentOctober 5, 2020Sample Size80Recruitment StatusActively recruitingPrimary Outcome(s)The primary outcome will be the child's total observed distress score during the IV procedure as measured on the Observational Signs of Behavioral Distress- Revised (OSBD-R) tool.Key Secondary OutcomesSecondary outcomes include: (a) the child's self- reported pain score during the IV procedure, using an 11-point 0-10 verbal Numerical Rating Scale (vNRS); (b) the child's self-reported fear score during the IV insertion as measured by the Children's Fear Scale (CFS); (c) parental/caregiver anxiety associated with the procedure, a sasessed by the State Trait Anxiety Inventory - State Trait Revised Version (STAI-S, Form Y); (d) satisfaction with the procedure for the child, their parent/caregiver and the nurse inserting the IV, as assessed by a 5-point Likert scale; and (e) the proportion of children who experience adverse events related to the study intervention.Ethics ReviewUniversity of Alberta Research Ethics Board # Pro00095418Completion date-Summary Results-IPD sharing statementDe-identified data can be shared, on a case-by-case		
previous enrollment in this study.Study TypeRandomized Controlled Superiority TrialDate of First EnrollmentOctober 5, 2020Sample Size80Recruitment StatusActively recruitingPrimary Outcome(s)The primary outcome will be the child's total observed distress score during the IV procedure as measured on the Observational Signs of Behavioral Distress- Revised (OSBD-R) tool.Key Secondary OutcomesSecondary outcomes include: (a) the child's self- reported pain score during the IV procedure, using an 11-point 0-10 verbal Numerical Rating Scale (vNRS); (b) the child's self-reported fear score during the IV insertion as measured by the Children's Fear Scale (CFS); (c) parental/caregiver anxiety associated with the procedure, as assessed by the State Trait Anxiety Inventory - State Trait Revised Version (STAI-S, Form Y); (d) satisfaction with the procedure for the child, their parent/caregiver and the nurse inserting the IV, as assessed by a 5-point Likett scale; and (e) the proportion of children who experience adverse events related to the study intervention.Ethics ReviewUniversity of Alberta Research Ethics Board # Pro0095418Completion date-PD sharing statementDe-identified data can be shared, on a case-by-case		
Study TypeRandomized Controlled Superiority TrialDate of First EnrollmentOctober 5, 2020Sample Size80Recruitment StatusActively recruitingPrimary Outcome(s)The primary outcome will be the child's total observed distress score during the IV procedure as measured on the Observational Signs of Behavioral Distress- Revised (OSBD-R) tool.Key Secondary OutcomesSecondary outcomes include: (a) the child's self- reported pain score during the IV procedure, using an 11-point 0-10 verbal Numerical Rating Scale (vNRS); (b) the child's self-reported fear score during the IV insertion as measured by the Children's Fear Scale (CFS); (c) parental/caregiver anxiety associated with the procedure, as assessed by the State Trait Anxiety Inventory - State Trait Revised Version (STAI-S, Form Y); (d) satisfaction with the procedure for the child, their parent/caregiver and the nurse inserting the IV, as assessed by a 5-point Likert scale; and (e) the proportion of children who experience adverse events related to the study intervention.Ethics ReviewUniversity of Alberta Research Ethics Board # Pro00095418Completion dateSummary ResultsIPD sharing statementDe-identified data can be shared, on a case-by-case		
Date of First EnrollmentOctober 5, 2020Sample Size80Recruitment StatusActively recruitingPrimary Outcome(s)The primary outcome will be the child's total observed distress score during the IV procedure as measured on the Observational Signs of Behavioral Distress- Revised (OSBD-R) tool.Key Secondary OutcomesSecondary outcomes include: (a) the child's self- reported pain score during the IV procedure, using an 11-point 0-10 verbal Numerical Rating Scale (vNRS); (b) the child's self-reported fear score during the IV insertion as measured by the Children's Fear Scale (CFS); (c) parental/caregiver anxiety associated with the procedure, as assessed by the State Trait Anxiety Inventory - State Trait Revised Version (STAI-S, Form Y); (d) satisfaction with the procedure for the child, their parent/caregiver and the nurse inserting the IV, as assessed by a 5-point Likert scale; and (e) the proportion of children who experience adverse events related to the study intervention.Ethics ReviewUniversity of Alberta Research Ethics Board # Pro00095418Completion date-Summary Results-IPD sharing statementDe-identified data can be shared, on a case-by-case	Study Type	1 ž
Sample Size80Recruitment StatusActively recruitingPrimary Outcome(s)The primary outcome will be the child's total observed distress score during the IV procedure as measured on the Observational Signs of Behavioral Distress- Revised (OSBD-R) tool.Key Secondary OutcomesSecondary outcomes include: (a) the child's self- reported pain score during the IV procedure, using an 11-point 0-10 verbal Numerical Rating Scale (vNRS); (b) the child's self-reported fear score during the IV insertion as measured by the Children's Fear Scale (CFS); (c) parental/caregiver anxiety associated with the procedure, as assessed by the State Trait Anxiety Inventory - State Trait Revised Version (STAI-S, Form Y); (d) satisfaction with the procedure for the child, their parent/caregiver and the nurse inserting the IV, as assessed by a 5-point Likert scale; and (e) the proportion of children who experience adverse events related to the study intervention.Ethics ReviewUniversity of Alberta Research Ethics Board # Pro00095418Completion date-PD sharing statementDe-identified data can be shared, on a case-by-case		1 ž
Recruitment StatusActively recruitingPrimary Outcome(s)The primary outcome will be the child's total observed distress score during the IV procedure as measured on the Observational Signs of Behavioral Distress- Revised (OSBD-R) tool.Key Secondary OutcomesSecondary outcomes include: (a) the child's self- reported pain score during the IV procedure, using an 11-point 0-10 verbal Numerical Rating Scale (vNRS); (b) the child's self-reported fear score during the IV insertion as measured by the Children's Fear Scale (CFS); (c) parental/caregiver anxiety associated with the procedure, as assessed by the State Trait Anxiety Inventory - State Trait Revised Version (STAI-S, Form Y); (d) satisfaction with the procedure for the child, their parent/caregiver and the nurse inserting the IV, as assessed by a 5-point Likert scale; and (e) the proportion of children who experience adverse events related to the study intervention.Ethics ReviewUniversity of Alberta Research Ethics Board # Pro00095418Completion date-Summary Results-IPD sharing statementDe-identified data can be shared, on a case-by-case		· · · · · · · · · · · · · · · · · · ·
Primary Outcome(s)The primary outcome will be the child's total observed distress score during the IV procedure as measured on the Observational Signs of Behavioral Distress- Revised (OSBD-R) tool.Key Secondary OutcomesSecondary outcomes include: (a) the child's self- reported pain score during the IV procedure, using an 11-point 0-10 verbal Numerical Rating Scale (vNRS); (b) the child's self-reported fear score during the IV insertion as measured by the Children's Fear Scale (CFS); (c) parental/caregiver anxiety associated with the procedure, as assessed by the State Trait Anxiety Inventory - State Trait Revised Version (STAI-S, Form Y); (d) satisfaction with the procedure for the child, their parent/caregiver and the nurse inserting the IV, as assessed by a 5-point Likert scale; and (e) the proportion of children who experience adverse events related to the study intervention.Ethics ReviewUniversity of Alberta Research Ethics Board # Pro00095418Completion date-Summary Results-IPD sharing statementDe-identified data can be shared, on a case-by-case	1	
distress score during the IV procedure as measured on the Observational Signs of Behavioral Distress- Revised (OSBD-R) tool.Key Secondary OutcomesSecondary outcomes include: (a) the child's self- reported pain score during the IV procedure, using an 11-point 0-10 verbal Numerical Rating Scale (vNRS); (b) the child's self-reported fear score during the IV insertion as measured by the Children's Fear Scale (CFS); (c) parental/caregiver anxiety associated with the procedure, as assessed by the State Trait Anxiety Inventory - State Trait Revised Version (STAI-S, Form Y); (d) satisfaction with the procedure for the child, their parent/caregiver and the nurse inserting the IV, as assessed by a 5-point Likert scale; and (e) the proportion of children who experience adverse events related to the study intervention.Ethics ReviewUniversity of Alberta Research Ethics Board # Pro00095418Completion date-Summary Results-IPD sharing statementDe-identified data can be shared, on a case-by-case		
the Observational Signs of Behavioral Distress- Revised (OSBD-R) tool.Key Secondary OutcomesSecondary outcomes include: (a) the child's self- reported pain score during the IV procedure, using an 11-point 0-10 verbal Numerical Rating Scale (vNRS); (b) the child's self-reported fear score during the IV insertion as measured by the Children's Fear Scale (CFS); (c) parental/caregiver anxiety associated with the procedure, as assessed by the State Trait Anxiety Inventory - State Trait Revised Version (STAI-S, Form Y); (d) satisfaction with the procedure for the child, their parent/caregiver and the nurse inserting the IV, as assessed by a 5-point Likert scale; and (e) the proportion of children who experience adverse events related to the study intervention.Ethics ReviewUniversity of Alberta Research Ethics Board # Pro00095418Completion date-Summary Results-IPD sharing statementDe-identified data can be shared, on a case-by-case	Primary Outcome(s)	1 5
Revised (OSBD-R) tool.Key Secondary OutcomesSecondary outcomes include: (a) the child's self- reported pain score during the IV procedure, using an 11-point 0-10 verbal Numerical Rating Scale (vNRS); (b) the child's self-reported fear score during the IV insertion as measured by the Children's Fear Scale (CFS); (c) parental/caregiver anxiety associated with the procedure, as assessed by the State Trait Anxiety Inventory - State Trait Revised Version (STAI-S, Form Y); (d) satisfaction with the procedure for the child, their parent/caregiver and the nurse inserting the IV, as assessed by a 5-point Likert scale; and (c) the proportion of children who experience adverse events related to the study intervention.Ethics ReviewUniversity of Alberta Research Ethics Board # Pro00095418Completion date-Summary Results-IPD sharing statementDe-identified data can be shared, on a case-by-case		e 1
Key Secondary OutcomesSecondary outcomes include: (a) the child's self- reported pain score during the IV procedure, using an 11-point 0-10 verbal Numerical Rating Scale (vNRS); (b) the child's self-reported fear score during the IV insertion as measured by the Children's Fear Scale (CFS); (c) parental/caregiver anxiety associated with the procedure, as assessed by the State Trait Anxiety Inventory - State Trait Revised Version (STAI-S, Form Y); (d) satisfaction with the procedure for the child, their parent/caregiver and the nurse inserting the IV, as assessed by a 5-point Likert scale; and (e) the proportion of children who experience adverse events related to the study intervention.Ethics ReviewUniversity of Alberta Research Ethics Board # Pro00095418Completion date-Summary Results-IPD sharing statementDe-identified data can be shared, on a case-by-case		e e
reported pain score during the IV procedure, using an 11-point 0-10 verbal Numerical Rating Scale (vNRS); (b) the child's self-reported fear score during the IV insertion as measured by the Children's Fear Scale (CFS); (c) parental/caregiver anxiety associated with the procedure, as assessed by the State Trait Anxiety Inventory - State Trait Revised Version (STAI-S, Form Y); (d) satisfaction with the procedure for the child, their parent/caregiver and the nurse inserting the IV, as assessed by a 5-point Likert scale; and (e) the proportion of children who experience adverse events related to the study intervention.Ethics ReviewUniversity of Alberta Research Ethics Board # Pro00095418Completion date-Summary Results-IPD sharing statementDe-identified data can be shared, on a case-by-case		
11-point 0-10 verbal Numerical Rating Scale (vNRS); (b) the child's self-reported fear score during the IV insertion as measured by the Children's Fear Scale (CFS); (c) parental/caregiver anxiety associated with the procedure, as assessed by the State Trait Anxiety Inventory - State Trait Revised Version (STAI-S, Form Y); (d) satisfaction with the procedure for the child, their parent/caregiver and the nurse inserting the IV, as assessed by a 5-point Likert scale; and (e) the proportion of children who experience adverse events related to the study intervention.Ethics ReviewUniversity of Alberta Research Ethics Board # Pro00095418Completion date-Summary Results-IPD sharing statementDe-identified data can be shared, on a case-by-case	Key Secondary Outcomes	5
(b) the child's self-reported fear score during the IV insertion as measured by the Children's Fear Scale (CFS); (c) parental/caregiver anxiety associated with the procedure, as assessed by the State Trait Anxiety Inventory - State Trait Revised Version (STAI-S, Form Y); (d) satisfaction with the procedure for the child, their parent/caregiver and the nurse inserting the IV, as assessed by a 5-point Likert scale; and (e) the proportion of children who experience adverse events related to the study intervention.Ethics ReviewUniversity of Alberta Research Ethics Board # Pro00095418Completion date-Summary Results-IPD sharing statementDe-identified data can be shared, on a case-by-case		
insertion as measured by the Children's Fear Scale (CFS); (c) parental/caregiver anxiety associated with the procedure, as assessed by the State Trait Anxiety Inventory - State Trait Revised Version (STAI-S, Form Y); (d) satisfaction with the procedure for the child, their parent/caregiver and the nurse inserting the IV, as assessed by a 5-point Likert scale; and (e) the proportion of children who experience adverse events related to the study intervention.Ethics ReviewUniversity of Alberta Research Ethics Board # Pro00095418Completion date-Summary Results-IPD sharing statementDe-identified data can be shared, on a case-by-case		
(CFS); (c) parental/caregiver anxiety associated with the procedure, as assessed by the State Trait Anxiety Inventory - State Trait Revised Version (STAI-S, Form Y); (d) satisfaction with the procedure for the child, their parent/caregiver and the nurse inserting the IV, as assessed by a 5-point Likert scale; and (e) the proportion of children who experience adverse events related to the study intervention.Ethics ReviewUniversity of Alberta Research Ethics Board # Pro00095418Completion date-Summary Results-IPD sharing statementDe-identified data can be shared, on a case-by-case		(b) the child's self-reported fear score during the IV
the procedure, as assessed by the State Trait Anxiety Inventory - State Trait Revised Version (STAI-S, Form Y); (d) satisfaction with the procedure for the child, their parent/caregiver and the nurse inserting the IV, as assessed by a 5-point Likert scale; and (e) the proportion of children who experience adverse events related to the study intervention.Ethics ReviewUniversity of Alberta Research Ethics Board # Pro00095418Completion date-Summary Results-IPD sharing statementDe-identified data can be shared, on a case-by-case		insertion as measured by the Children's Fear Scale
Inventory - State Trait Revised Version (STAI-S, Form Y); (d) satisfaction with the procedure for the child, their parent/caregiver and the nurse inserting the IV, as assessed by a 5-point Likert scale; and (e) the proportion of children who experience adverse events related to the study intervention.Ethics ReviewUniversity of Alberta Research Ethics Board # Pro00095418Completion date-Summary Results-IPD sharing statementDe-identified data can be shared, on a case-by-case		(CFS); (c) parental/caregiver anxiety associated with
Form Y); (d) satisfaction with the procedure for the child, their parent/caregiver and the nurse inserting the IV, as assessed by a 5-point Likert scale; and (e) the proportion of children who experience adverse events related to the study intervention.Ethics ReviewUniversity of Alberta Research Ethics Board # Pro00095418Completion date-Summary Results-IPD sharing statementDe-identified data can be shared, on a case-by-case		the procedure, as assessed by the State Trait Anxiety
child, their parent/caregiver and the nurse inserting the IV, as assessed by a 5-point Likert scale; and (e) the proportion of children who experience adverse events related to the study intervention.Ethics ReviewUniversity of Alberta Research Ethics Board # Pro00095418Completion date-Summary Results-IPD sharing statementDe-identified data can be shared, on a case-by-case		Inventory - State Trait Revised Version (STAI-S,
child, their parent/caregiver and the nurse inserting the IV, as assessed by a 5-point Likert scale; and (e) the proportion of children who experience adverse events related to the study intervention.Ethics ReviewUniversity of Alberta Research Ethics Board # Pro00095418Completion date-Summary Results-IPD sharing statementDe-identified data can be shared, on a case-by-case		Form Y); (d) satisfaction with the procedure for the
IV, as assessed by a 5-point Likert scale; and (e) the proportion of children who experience adverse events related to the study intervention.Ethics ReviewUniversity of Alberta Research Ethics Board # Pro00095418Completion date-Summary Results-IPD sharing statementDe-identified data can be shared, on a case-by-case		
proportion of children who experience adverse events related to the study intervention.Ethics ReviewUniversity of Alberta Research Ethics Board # Pro00095418Completion date-Summary Results-IPD sharing statementDe-identified data can be shared, on a case-by-case		
related to the study intervention.Ethics ReviewUniversity of Alberta Research Ethics Board # Pro00095418Completion date-Summary Results-IPD sharing statementDe-identified data can be shared, on a case-by-case		
Ethics ReviewUniversity of Alberta Research Ethics Board # Pro00095418Completion date-Summary Results-IPD sharing statementDe-identified data can be shared, on a case-by-case		
Pro00095418 Completion date - Summary Results - IPD sharing statement De-identified data can be shared, on a case-by-case	Ethics Review	
Completion date-Summary Results-IPD sharing statementDe-identified data can be shared, on a case-by-case		
IPD sharing statementDe-identified data can be shared, on a case-by-case	Completion date	-
	Summary Results	-
		De-identified data can be shared, on a case-by-case
		basis, upon discussion with the principal investigator.

Ali S, Rajagopal M, et al

Setting and Study Period

This study will be conducted in the Stollery Children's Hospital (SCH) emergency department in Edmonton, Alberta, Canada. The SCH is a tertiary care hospital whose annual ED census is typically approximately 60,000. The 2020 ED census for the SCH was reduced to 36,899 due to the COVID-19 pandemic. Recruitment launched in September 2020 and is expected to end in March 2022. Based on our team's previous experience conducting research in this setting, and considering the ongoing pandemic-related considerations, we anticipate 18 months of recruitment to meet our overall target of 80 patients.

Eligibility and Exclusion Criteria

Children will be eligible if they are 6 to 17 years, require an IV placement during their ED visit, and have received topical anesthetic cream for their IV placement. This age group was chosen as they can reliably self-report pain and are expected to benefit from the virtual reality study intervention, based on prior studies. [44] Due to ethical and pragmatic considerations, we insisted that children must be receiving topical anesthetic cream for IV placement to be eligible for our study, as it is effective and considered standard of care within our hospital. [10] Exclusion criteria are detailed in Table 1.

Study Intervention and Comparison

The intervention will include the use of an immersive VR application that will engage children for the duration of the IV procedure. The VR intervention will be provided in addition to standard of care. The child will wear the VR goggles (Oculus Quest, Oculus, Facebook Technologies, LLC; see Figure 1) and small handheld controllers (optional) can be used to interact with the virtual environment and change settings. The VR goggles will occlude the patient's view of the treatment room, and a pair of noise-cancelling headphones (optional) can be used to block out ambient hospital sounds. Together, this will provide the child with a unique vivid experience of being fully immersed or "present" inside the 3D virtual world. The child will be presented with one of two VR menu options, one for novice users and another for more experienced users. The menus will have pre-selected VR applications that are suitable for use during the IV procedure and will include a combination of interactive games and immersive 3D movies designed specifically for a virtual reality experience (see Figure 2). The choice of applications was based on consultation with the Stollery Children's Hospital Youth Advisory Committee prior to commencing the study. The shortlisted applications were then tested by the principal investigators, other team members, and youth. The research assistant (RA), who will be trained in proper equipment use and troubleshooting, will help the child with selecting and running the VR game/movie. Based on child and nursing preference, children may either sit up or lie in a supine position for the duration of the procedure. The chosen VR games will not require the child to move their torso or both arms, to not interfere with the IV placement. The VR goggles can be removed at any time during the procedure if the child so desires. The game/application selected by the child will be recorded on the case report form.

The Virtual Reality Study Protocol Version 1.0

The control group will receive departmental standard of care which will include topical anesthetic cream (mandatory for inclusion in the study) and may include parent/caregiver support, child life services, nursing support, and other support strategies at the discretion of the ED clinical care team and the family. Child life services include pre-procedural education, distraction and coaching, intra-procedural presence, and post-procedural support and prizes. At present, there is no single established distraction therapy or routine that is consistently employed for IV procedures within our ED. Thus, for pragmatic and ethical considerations, it is felt that the new study VR intervention should be compared to what is currently already in practice (i.e., standard of care). Generally, VR technology is not employed by the nursing staff for distracting the child. However, other forms of technology (i.e., smart phones, tablets) will *not* be prohibited in the control group if the family chooses to offer them. Use of other devices and distraction techniques will be documented.

Randomization, Allocation Concealment, and Blinding

Randomization will be determined using an online randomization tool hosted on the REDCap [45] (Research Electronic Data Capture) platform. Following documentation of informed consent and assent, the RA will obtain the computer-generated randomized assignment for the child by clicking on the 'Randomize' button within the study-specific REDCap case report form. Allocation will be concealed from the research staff, ED clinical staff and the family until this point. However, due to the nature of the intervention, it is not possible to maintain blinding once the child has been randomized.

Children and their parents/caregivers will be informed that the study will evaluate and compare different forms of distraction, however they will not be made aware of the study hypothesis for the VR intervention. Furthermore, the statistician will be blinded to treatment assignment by using randomization codes until data analysis is complete.

Recruitment and Data Collection

Participant recruitment will occur in the SCH ED when RAs are on-site, from approximately 15:00 to 23:00 daily. Based on our team's previous research, this time frame corresponds with peak ED volume. RAs will screen the electronic ED track board and communicate with on-site clinical staff to identify potentially eligible patients. The RA will then further assess eligibility based on the inclusion/exclusion criteria detailed above. If the child is deemed eligible and the family is willing to participate, the RA will obtain written informed consent from the parent/ caregiver and assent from the child (See Appendix 1). One parent/caregiver for each child will be asked to provide consent and complete all relevant study questionnaires.

Prior to the beginning of the IV procedure, the RA will collect baseline information, including: baseline heart rate, pre-procedure distress, fear, and pain scores from the child, and pre-procedure anxiety score from the parent/caregiver. The RA will then access the randomization tool on REDCap to reveal the child's group assignment (VR intervention or Control).

Ali S, Rajagopal M, et al

For the VR intervention group, the RA will set up the VR equipment and spend approximately 5-10 minutes explaining the intervention to the child, including proper use of the goggles and controller. The RA will then help the child put on and secure the goggles and headphones, and hand them the controller. They will document the time required for equipment set up as well as any technical challenges encountered. As per hospital infection control policy, all VR equipment including the goggles, headphones and controller will be sanitized with disinfectant wipes between participants. A disposable one-time use cover will be placed on the goggles for each participant. For all participants (both study arms), the RA will begin video recording the child five minutes prior to the start of the procedure and continue until 5 minutes post-procedure, to allow for complete coding of OSBD-R distress scores at a later time.

For all participants (both study arms), the staff nurse will insert the IV following institutional protocol. In keeping with the pragmatic design of the trial, no additional or study-specific instructions will be provided to either nurses or parents/caregivers regarding their behaviour during the procedure. For purposes of the study, the start of the IV insertion procedure will be marked by the cleaning of the IV site by the staff nurse. The end of the procedure will be defined by the last point of contact by the staff nurse (i.e., taping cannula in place with or without arm board, wrapping arm with gauze and taping the gauze in place).

During the procedure, the RA will closely monitor the child for any adverse effects. The child will also be asked to let the team know immediately if they are experiencing any adverse events or discomfort related to the VR intervention (i.e., dizziness, nausea, headache). The VR intervention can be discontinued (i.e., the headset can be removed) at any time, at the discretion of the child or clinical team. If an adverse event were to occur, the clinical team will be notified, and details will be logged in the REDCap adverse event log. Additionally, the RA will make a note of any technical failures or issues associated with the VR equipment during enrollment.

Immediately following the first *attempt* at IV placement (regardless of whether it was successful), the RA will collect post-procedure distress, fear and pain scores from the child, and post-procedure anxiety score from the parent/caregiver. A few minutes after completion of the IV placement, satisfaction and acceptability questionnaires will be completed with the child, parent /caregiver as well as the staff nurse responsible for

inserting the IV. Five minutes after the procedure is completed, the RA will stop the

video recording. The duration of the procedure and total number of IV attempts will be documented. If the first attempt at placement is unsuccessful, any additional attempts will occur after all relevant study questionnaires/measurements have been completed.

Demographic information, previous history and visit details will also be collected from the family and the child's medical chart. See Figure 3 for study flow schematic.

Outcome Measures

Our primary outcome is **distress**. Our secondary outcomes are (a) pain; (b) fear; (c) the parental/caregiver anxiety; and (d) parental/caregiver and nurse satisfaction with the procedure in the intervention; and (e) safety.

The Virtual Reality Study Protocol Version 1.0

Our primary outcome measure will be the child's total distress score during the IV procedure. Distress associated with the procedure will be assessed using the Observational Scale of Behavioral Distress-Revised (OSBD-R). The OSBD-R is a validated scale that is widely used to measure pain and distress associated with various medical procedures in children. [46-48] The tool assesses eight specific behaviors that are indicative of distress and are weighted according to intensity: information seeking, crying, screaming, restraint, verbal resistance, emotional support, verbal pain, and flailing. Study participants will be videotaped for the duration of the IV procedure as well as for a few minutes before and after; distress will be scored pre-, during, and postprocedure. Two RAs who are trained in the use of the tool will independently observe the videotapes and record the frequency of each of the eight behaviors during continuous 15second intervals. To ensure high inter-rater reliability, the first 10% of coded videos will be analyzed for inter-rater reliability and RAs will be provided with feedback and retraining, as needed, prior to coding the remaining videos. The mean OSBD-R scores between the two RAs will be used as the final scores. This standardized procedure for OSBD-R has been successfully used in previous research evaluating distraction. [29, 49-52] This scale demonstrates high inter-rater reliability as well as moderate to high correlations with other behavioral measures of distress. [49, 53-54]

Our principal secondary outcome measure will be the child's pain score during the IV procedure. Pain will be measured using an 11-point verbal Numerical Rating Scale (vNRS) ranging from 0 (no pain) to 10 (worst possible pain). This scale is a commonly used pain measurement tool in pediatric acute pain studies and is validated for use in children 6-17 years of age. [55-58] Pain scores will be self-reported by children both before and immediately following the IV procedure.

Fear will be measured using the Children's Fear Scale (CFS) [4, 59]. This scale depicts five faces representing increasing levels of anxiety, where the left-most face depicts "not scared at all" (score=0) and the right most-face means "most scared possible" (score=4). The CFS is an adaptation of the adult Faces Anxiety Scale [59] and has been validated to measure fear in children undergoing painful medical procedures. [4] Children will be asked to independently rate their fear both before and immediately following the IV procedure.

Parental/Caregiver anxiety will be measured with the State Trait Anxiety Inventory – State Scale Revised Version (STAI-S, Form Y), a validated and commonly used version of STAI, which has improved psychometric properties. [60] Parents/caregivers will be asked to complete the STAI questionnaire both before and immediately following the IV procedure. The Virtual Reality Study Protocol Version 1.0

Parent/caregiver and nurse satisfaction with the procedure will be measured using a 5-point Likert scale, ranging from 1 "Very dissatisfied" to 5 "Very satisfied". Child satisfaction with the procedure will be measured using a 5-point Likert scale, ranging from 1 "Not at all happy" to 5 "Very happy". Satisfaction scores will be collected immediately following the IV procedure.

Safety of the VR intervention will be determined by assessing the frequency of adverse events post intervention. Specifically, nausea will be self-rated by children immediately following the intervention, using the Baxter Retching Faces (BARF) scale [61]. This scale consists of 6 faces depicting increasing levels of nausea, with assigned scores ranging from 0 to 10. The BARF scale is widely used in medical research and has demonstrated construct, content, and convergent validity as a tool to measure nausea in children. [61] The presence of other adverse events (i.e., dizziness) will also be recorded by the RA. Children who are presenting with nausea, vomiting, dizziness or migraines *prior* to enrollment will be excluded from the study to avoid exacerbating these conditions with the use of the VR equipment.

Sample Size

The sample size for the study is 80 patients overall. Sample size calculations were conducted using a two-tailed, two-sample Mann-Whitney test for the primary outcome of observed behavioral distress based on data from the team's previous trial of digital distraction. To detect a large effect size of 0.6 on the OSBD-R (which was observed in a previous trial), given a Type I error of 0.05 and 80% power, the study will require 35 patients for each of the two study arms. To account for attrition and technical recording failures, the team will plan to over-recruit by 10-15%, for an overall total of 80 patients. This will allow sufficient power to find a difference in the primary outcome if a difference truly exists.

Statistical Methods

Statistical analyses will be conducted using statistical software SAS (version 9: SAS Institute, Cary, NC). The significance level will be set at 0.05. Baseline variables will be described using appropriate summary statistics for each group. Imbalances between groups for key baseline variables will indicate the need for further adjusted analyses. For the primary outcome of observed behavioral distress, total OSBD-R scores will be compared between the two groups using independent samples t-tests if they are normally distributed or Mann-Whitney U-tests if they are skewed (the Sidak correction procedure will be used to reduce the probability of a Type I error). Additional model-based analyses (multiple linear regression) will be conducted, as needed, with behavioural distress as the response variable, pre-procedure behavioral distress and group indicators as the explanatory variables along with some possible effect modifiers such as age, sex, and parental/caregiver anxiety levels. Our primary analysis will be based on an intention-totreat approach where all children who were randomly assigned to a study group will be included in the group to which they were randomized. Where cell sizes are small or data are sparse or missing, proxy information or appropriate imputation methods will be used as needed. Similar approaches will be used to compare the groups with respect to secondary outcomes if appropriate.

Patient and Public Involvement

The team's parent advisor (KS) has provided ongoing input on the study protocol and design, and has provided valuable feedback on the content, flow and readability of the consent forms and data collection forms. The Stollery Youth Advisory Council, led by team member AP, provided input on the study design, outcomes measures, and types of virtual reality applications that might be engaging and practical for our study population. AP also reviewed the study protocol and related documents to ensure that the outcomes and tools were patient-relevant and age-appropriate. Following recruitment completion, parent and youth advisors will be further engaged to discuss study results and dissemination plans in the context of patient- and family-centered care.

Data Management and Confidentiality

Data will be entered into a secure online REDCap [45] database hosted by the Women and Children's Health Research Institute (WCHRI). (See Appendix 2 for Case Report Form.) WCHRI's REDCap installation is a validated electronic, web-based data capture system housed in a secure data center at the University of Alberta. Data is entered into REDCap through a web-based interface using 128-bit SSL encryption. Each team member will be granted an individual username/ password and will require additional two factor authentication to log in. All datasets used for statistical analysis will be encrypted and devoid of any patient identifiers. For internal data quality control, a secure master list will be maintained to accurately link study IDs to the patient's medical record.

Selected data elements will be validated electronically throughout the recruitment period and any discrepancies will be assigned to team members for timely resolution. REDCap includes internal quality checks, such as automatic range checks, to identify data that appear inconsistent, incomplete, or inaccurate.

Study data will be entered directly into REDCap in real-time via research iPads or, in some cases (i.e., parent/caregiver indicate a preference to complete paper-based questionnaires), responses may be collected on paper first and then transcribed into REDCap by a trained RA. All paper documents (including study questionnaires, consent/assent forms, and the master list) will be stored in a locked cabinet in a secure location that is only accessible to authorized research staff members. Study videos will be stored electronically in a secure institutional shared drive with restricted access to study staff. Videos will be stored on a secure server and computers at the University of Alberta. Following completion of the study, all data will continue to be kept in a secure location for five years as dictated by the research ethics board.

ETHICS AND DISSEMINATION

This study has received approval from the Health Research Ethics Board (HREB) at the University of Alberta (HREB identifier: Pro00073476). Any amendments to the study protocol or documents will be submitted for HREB review and will receive approval prior to implementation. Significant protocol amendments will also be reflected online on

Ali S, Rajagopal M, et al

the clinicaltrials.gov study registration. This study has also received operational approval from the SCH ED.

All children will receive the best possible care for their presenting complaint, regardless of whether they choose to participate. It is possible that patients in the VR intervention group may experience nausea, mild motion sickness or dizziness, however these effects are rare in children and adolescents, ranging from 0-5%. [62, 63] VR applications have been selected appropriately to minimize these discomforts, and children are monitored closely throughout the study for any adverse effects. Children experiencing nausea, vomiting, dizziness or migraine headaches prior to enrollment will be excluded to avoid potential exacerbation. Study participation is unlikely to prolong the ED length of stay. For infection-control purposes, children screening positive for 'influenza-like illness' (as per ED screening criteria) are excluded to prevent potential contamination of the VR equipment.

Due to resource/logistical constraints, study recruitment will be limited to Englishspeaking families or those with their own interpreter, at a single recruiting center, and during RA shift hours only. Critically ill children requiring immediate IV insertion will also be excluded to avoid delaying medical care. This may limit the generalizability of the study findings. We will not be controlling for the type of distraction used in the standard of care arm, but we will record what was employed. While this may create some heterogeneity in the comparison arm of the study, it will be a pragmatic reflection of clinical reality. Due to the nature of the intervention, blinding is not possible for the participants or the research personnel, though the statistician will be blind to study group.

The study team plans to publish trial results in a high-impact, peer-reviewed journal and present results at national and international meetings; authorship eligibility will be determined by employing the International Committee of Medical Journal Editors' recommended guidelines. [64] Statistical code and dataset can be made available upon request.

Competing Interests None declared.

Patient Consent After assessing eligibility based on the outlined inclusion/exclusion criteria, research assistants will obtain consent from the parents/caregivers (and assent from children older than 6 years) prior to enrolling the child in the study. The research assistant will provide both a verbal and written explanation of the study to the family. The family will be given an opportunity to review the consent/assent forms in private and can ask the research assistant any questions they might have prior to signing the consent/assent forms. The family is free to withdraw at any point during the study.

<u>Acknowledgments</u> The authors would like to thank the members of the Stollery Youth Advisory Council, who provided valuable input on the study design and gaming/application choices for the virtual reality headsets.

The Virtual Reality Study Protocol Version 1.0

FUNDING STATEMENT

This work is funded by the generosity of the Stollery Children's Hospital Foundation through the Women and Children's Health Research Institute Innovation Grant. Purchase of the virtual reality goggles was facilitated through a generous small equipment grant from the Stollery Children's Hospital Foundation. The funders do not have any role in the collection, management, analysis, or interpretation of data; writing of the report; or the decision to submit the report for publication. Dr. Hartling is supported by a Canada Research Chair in Knowledge Synthesis and Translation and is a Distinguished Researchers with the Stollery Science Lab supported by the Stollery Children's Hospital or oper terien only Foundation.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

AUTHOR CONTRIBUTIONS

Dr. Samina Ali (SA) is a pediatric emergency clinician-researcher and Professor of Pediatrics & Emergency Medicine at the University of Alberta. She co-developed and revised the protocol and co-drafted the protocol paper. She chose the previously validated tools for measuring the primary outcomes.

Manasi Rajagopal (MR) is the program lead for the Pediatric Emergency Medicine research program at the University of Alberta and co-principal investigator of this study. She co-developed the study protocol, co-drafted the protocol paper, and will operationalize the study.

Dr. Jennifer Stinson (JS) is the Mary Jo Haddad Nursing Chair in Child Health at the Hospital for Sick Children's Research Institute and a nurse practitioner in the Department of Anesthesia's chronic pain program at the hospital. She assisted with the study design and protocol revision.

Dr. Keon Ma is a pediatric trainee at the University of Calgary, with expertise in OSBD-R coding. He assisted with the study design and protocol revision.

Ben Vandermeer (BV) led the statistical analysis planning and contributed to protocol revision.

Bailey Felkar (BF) is a child life specialist at the Stollery ED with expertise in managing children's pain and distress in the ED setting. She assisted with the study design and protocol revision.

Kurt Schreiner (KS) is a family partner who has provided input into study outcomes to ensure family-relevant outcomes are chosen and will inform our knowledge translation efforts to the public.

Amanda Proctor (AP) is the coordinator of the Stollery Youth Advisory Council. Together with the council, she informed programming choices for the virtual reality devices and has reviewed the protocol and related documents to ensure that the outcomes and tools are patient-relevant and age-appropriate.

Jennifer Plume (JP) is the acting director for Stollery child life services with expertise in managing children's pain and distress in the ED. She has informed study methods and will aid and support the development of our knowledge translation plan.

Dr. Lisa Hartling (LH) is a Professor in the Department of Pediatrics at the University of Alberta and Director of the Alberta Research Centre for Health Evidence (Edmonton, Canada). She assisted with the study design and drafting the protocol, and provides expertise in clinical trial methodology and statistical analyses.

The Virtual Reality Study Protocol Version 1.0

All authors have approved this final version of the protocol. None of the authors have financial or other conflicts of interests as they pertain to this study and its involved recruitment sites.

tor occr terien ont

Figures Legend

Figure 1. Child using virtual reality goggles in the emergency department Figure 2. Virtual Reality Game Menus Figure 3. Flow Diagram of Study Procedures

tor peer teriew only

tor peer terien ont

The Virtual Reality Study Protocol Version 1.0

REFERENCES

- 1. Stevens BJ, Abbott LK, Yamada J, et al; CIHR Team in Children's Pain. Epidemiology and management of painful procedures in children in Canadian hospitals, *Canadian Medical Association Journal*. 2011 Apr 19;183(7):E403-10.
- 2. Duff AJA. Incorporating psychological approaches into routine paediatric venepuncture, *Archives of Disease in Childhood* 2003;88:931-7 doi:10.1136/adc.88.10.931.
- 3. Sanchez Cristal N, Staab J, Chatham R, et al. Child Life Reduces Distress and Pain and Improves Family Satisfaction in the Pediatric Emergency Department, *Clin Pediatr (Phila)* 2018;57:1567-75 doi:10.1177/0009922818798386.
- 4. McMurtry CM, Noel M, Chambers CT, et al. Children's fear during procedural pain: Preliminary investigation of the Children's Fear Scale, *Health Psychology* 2011;30:780-8 doi:10.1037/a0024817.
- 5. McGrath PJ, McAlpine L. Psychologic perspectives on pediatric pain, *The Journal of Pediatrics* 1993;122:S2-8 doi:10.1016/S0022-3476(11)80002-8.
- 6. Drendel AL, Ali S. Ten Practical Ways to Make Your ED Practice Less Painful and More Child-Friendly, *Clinical Pediatric Emergency Medicine*. Volume 18, Issue 4, December 2017, 242- 255.
- 7. El-Housseiny AA, Alamoudi NM, Farsi NM, et al. Characteristics of dental fear among Arabic-speaking children: a descriptive study, *BMC Oral Health* 2014;14 doi:10.1186/1472-6831-14-118.
- 8. Fields H. How expectations influence pain, *Pain* 2018;159:S3-S10 doi:10.1097/j.pain.00000000001272.
- 9. Noel M, Rabbitts JA, Tai GG, et al. Remembering Pain after Surgery: A Longitudinal Examination of the Role of Pain Catastrophizing in Children's and Parents' Recall, *Pain* 2015;156:800 doi:10.1097/j.pain.000000000000102.
- 10. Trottier ED, Doré-Bergeron MJ, Chauvin-Kimoff L, et al. Managing pain and distress in children undergoing brief diagnostic and therapeutic procedures. [CPS Position Statement], *Paediatrics & Child Health* 2019;24:509-21.
- 11. Friedrichsdorf SJ, Eull D, Weidner CA. A Children's Comfort Promise: how can we do everything possible to prevent and treat pain in children using quality improvement strategies? *Pediatric Pain Letter* 2016;18:26-30.
- 12. Dumoulin S, Bouchard S, Ellis J, et al. A Randomized Controlled Trial on the Use of Virtual Reality for Needle-Related Procedures in Children and Adolescents in the Emergency Department. , *Games for Health Journal* 2019;8:285-93.
- 13. Jain S, Hegenbarth MA, Humiston SG, et al. Increasing ED use of jet injection of lidocaine for IV-related pain management , *Pediatrics* 2017;139:e20161697.
- 14. Chan E, Hovenden M, Ramage E, et al. Virtual Reality for Pediatric Needle Procedural Pain: Two Randomized Clinical Trials, *The Journal of Pediatrics* 2019;209:160,167.e4 doi:10.1016/j.jpeds.2019.02.034.
- 15. Gaskell S. Evidence-based guidelines for the management of invasive and/or distressing procedures with children, *British Journal of Social Psychology* 2019.
- 16. McCaul KD, Malott JM. Distraction and coping with pain, Pain 1985;23:315.
- 17. Manne SL, Bakeman R, Jacobsen PB, et al. An analysis of a behavioral intervention for children undergoing venipuncture, *Health Psychology* 1994;13:556-66.

4

5

6

7

8 9

10

11

12

13

14

15

16 17

18

19

20

21

22

23

24 25

26

27

28

29

30

31 32

33

34

35

36

37

38

39 40

41

42

43

44

45

46 47

48

49

50

51

52

53

54

60

18. Vessey JA, Carlson KL, McGill J. Use of distraction with children during an acute pain experience, Nursing Research 1994;43:369-72 doi:10.1097/00006199-199411000-00009. 19. Klassen JA, Liang Y, Tjosvold L, et al. Music for Pain and Anxiety in Children Undergoing Medical Procedures: A Systematic Review of Randomized Controlled Trials, Ambulatory Pediatrics 2008;8:117-28 doi:10.1016/j.ambp.2007.12.005. 20. Cohen LL, Blount RL, Panopoulos G. Nurse Coaching and Cartoon Distraction: An Efective and Practical Intervention to Reduce Child, Parent, and Nurse Distress During Immunizations, J Pediatr Psychol 1997;22:355-70 doi:10.1093/jpepsy/22.3.355. 21. Cassidy K, Reid GJ, McGrath PJ, et al. Watch Needle, Watch TV: Audiovisual Distraction in Preschool Immunization, Pain Med 2002;3:108-18 doi:10.1046/j.1526-4637.2002.02027.x. 22. Downey LVA, Zun LS. The Impact of Watching Cartoons for Distraction During Painful Procedures in the Emergency Department, Pediatric Emergency Care 2012;28:1033 doi:10.1097/PEC.0b013e31826cac1a. 23. Young T, Griffin E, Phillips E, et al. Music as Distraction in a Pediatric Emergency Department, Journal of Emergency Nursing 2010;36:472-3 doi:10.1016/j.jen.2010.05.014. 24. Ha YO, Kim HS. The effects of audiovisual distraction on children's pain during laceration repair, International Journal of Nursing Practice 2013;19:20-7 doi:10.1111/ijn.12165. 25. Gates M, Hartling L, Shulhan-Kilroy J, et al. Digital Technology Distraction for Acute Pain in Children: A Meta-analysis, Pediatrics 2020;145 doi:10.1542/peds.2019-1139. 26. Ahmadpour N, Randall H, Choksi H, et al. Virtual Reality interventions for acute and chronic pain management, International Journal of Biochemistry & Cell Biology 2019;114:105568. 27. Sikka N, Shu L, Ritchie B, et al. Virtual Reality-Assisted Pain, Anxiety, and Anger Management in the Emergency Department, *Telemedicine and e-Health* 2019. 28. Hoffman HG, Doctor JN, Patterson DR, et al. Use of virtual reality for adjunctive treatment of adolescent burn pain during wound care: A case report, Pain 2000;1-2:305-9. 29. Han S, Park J, Choi SI, et al. Effect of Immersive Virtual Reality Education Before Chest Radiography on Anxiety and Distress Among Pediatric Patients: A Randomized Clinical Trial, JAMA pediatrics 2019 doi:10.1001/jamapediatrics.2019.3000. 30. Shetty V, Suresh LR, Hegde AM. Effect of Virtual Reality Distraction on Pain and Anxiety During Dental Treatment in 5 to 8 Year Old Children, Journal of Clinical Pediatric Dentistry 2019;43:97-102. 31. Furman E, Jasinevicius TR, Bissada NF, et al. Virtual Reality Distraction for Pain Control During Periodontal Scaling and Root Planing Procedures, The Journal of the American Dental Association 2009;140:1508-16 doi:10.14219/jada.archive.2009.0102. 32. Schneider SM, Hood LE. Virtual Reality: A Distraction Intervention for Chemotherapy, Oncology nursing forum 2007;34:39-46 doi:10.1188/07.ONF.39-46.

The Virtual Reality Study Protocol Version 1.0

- 33. Gerardi M, Rothbaum BO, Ressler K, et al. Virtual reality exposure therapy using a virtual Iraq: Case report, *Journal of Traumatic Stress* 2008;21:209-13 doi:10.1002/jts.20331.
- 34. Parsons TD, Rizzo AA. Affective outcomes of virtual reality exposure therapy for anxiety and specific phobias: A meta-analysis, *Journal of Behavior Therapy and Experimental Psychiatry* 2008;39:250-61 doi:10.1016/j.jbtep.2007.07.007.
- 35. Botella C, Serrano B, Baños RM, et al. Virtual reality exposure-based therapy for the treatment of post-traumatic stress disorder: a review of its efficacy, the adequacy of the treatment protocol, and its acceptability, *Neuropsychiatr Dis Treat* 2015;11:2533-45 doi:10.2147/NDT.S89542.
- 36. Marco JH, Perpiñá C, Botella C. Effectiveness of cognitive behavioral therapy supported by virtual reality in the treatment of body image in eating disorders: One year follow-up, *Psychiatry Research* 2013;209:619-25 doi:10.1016/j.psychres.2013.02.023.
- 37. Litwin SP, Nguyen C, Hundert A, Stuart S, Liu D, Maguire B, Matava C, Stinson J. Virtual reality to reduce procedural pain during IV insertion in the pediatric emergency department: a pilot randomized controlled trial. The Clinical Journal of Pain. 2021 Feb 1;37(2):94-101.
- 38. Goldman RD, Behboudi A. Virtual reality for intravenous placement in the emergency department—a randomized controlled trial. European Journal of Pediatrics. 2021 Mar;180(3):725-31.
- 39. Chen YJ, Cheng SF, Lee PC, Lai CH, Hou IC, Chen CW. Distraction using virtual reality for children during intravenous injections in an emergency department: A randomised trial. Journal of clinical nursing. 2020 Feb;29(3-4):503-10.
- 40. Osmanlliu E, Trottier ED, Bailey B, Lagacé M, Certain M, Khadra C, Sanchez M, Thériault C, Paquin D, Côtes-Turpin C, Le May S. Distraction in the Emergency department using Virtual reality for INtravenous procedures in Children to Improve comfort (DEVINCI): a pilot pragmatic randomized controlled trial. Canadian Journal of Emergency Medicine. 2021 Jan;23(1):94-102.
- 41. Lambert V, Boylan P, Boran L, et al. Virtual reality distraction for acute pain in children, *The Cochrane database of systematic reviews* 2020;10 doi:10.1002/14651858.CD010686.pub2.
- 42. Czech O, Wrzeciono A, Rutkowska A, Guzik A, Kiper P, Rutkowski S. Virtual reality interventions for needle-related procedural pain, fear and anxiety—A systematic review and meta-analysis. Journal of clinical medicine. 2021 Jan;10(15):3248.
- 43. Chan A, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials, *Ann Intern Med* 2013;158:200-7 doi:10.7326/0003-4819-158-3-201302050-00583.
- 44. Hoffman HG, Rodriguez RA, Gonzalez M, et al. Immersive Virtual Reality as an Adjunctive Non-opioid Analgesic for Pre-dominantly Latin American Children With Large Severe Burn Wounds During Burn Wound Cleaning in the Intensive Care Unit: A Pilot Study, *Frontiers in human neuroscience* 2019;13 doi:10.3389/fnhum.2019.00262.
- 45. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational

The Virtual Reality Study Protocol Version 1.0

research informatics support, *Journal of Biomedical Informatics* 2009;42:377-81 doi:10.1016/j.jbi.2008.08.010.

- 46. Jay SM, Elliott C. Observation Scale of Behavioral Distress-Revised. Information procedures, definitions of behaviors, OSBD Interval Coding Form. 1986.
- 47. Jay SM, Elliott C. Behavioral observation scales for measuring children's distress: The effects of increased methodological rigor, *Journal of Consulting and Clinical Psychology* 1984;52:1106-7 doi:10.1037/0022-006X.52.6.1106.
- 48. Tucker CL, Slifer KJ, Dahlquist LM. Reliability and Validity of the Brief Behavioral Distress Scale: A Measure of Children's Distress During Invasive Medical Procedures, *J Pediatr Psychol* 2001;26:513-23 doi:10.1093/jpepsy/26.8.513.
- 49. Elliott CH, Jay SM, Woody P. An Observation Scale for Measuring Children's Distress During Medical Procedures, *J Pediatr Psychol* 1987;12:543-51 doi:10.1093/jpepsy/12.4.543.
- 50. Megel ME, Houser CW, Gleaves LS. Children's Responses to Immunizations: Lullabies as a Distraction, *Issues in Comprehensive Pediatric Nursing* 1998;21:129-45 doi:10.1080/014608698265456.
- 51. Noguchi LK. The Effect of Music Versus Nonmusic on Behavioral Signs of Distress and Self-Report of Pain in Pediatric Injection Patients, *J Music Ther* 2006;43:16-38 doi:10.1093/jmt/43.1.16.
- 52. Hartling L, Newton AS, Liang Y, et al. Music to Reduce Pain and Distress in the Pediatric Emergency Department: A Randomized Clinical Trial, *JAMA Pediatrics* 2013;167:826-35 doi:10.1001/jamapediatrics.2013.200.
- 53. Stevenson MD, Bivins CM, O'Brien K, et al. Child Life Intervention During Angiocatheter Insertion in the Pediatric Emergency Department, *Pediatric Emergency Care* 2005;21:712 doi:10.1097/01.pec.0000186423.84764.5a.
- Jay SM, Ozolins M, Elliott CH, et al. Assessment of children's distress during painful medical procedures, *Health Psychology* 1983;2:133-47 doi:10.1037/0278-6133.2.2.133.
- 55. von Baeyer CL. Children's self-report of pain intensity: what we know, where we are headed, *Pain research & management* 2009;14:39.
- 56. Miró J, Castarlenas E, de la Vega R, et al. Validity of three rating scales for measuring pain intensity in youths with physical disabilities, *Eur J Pain* 2016;20:130-7 doi:10.1002/ejp.704.
- 57. Castarlenas E, Jensen MP, von Baeyer CL, et al. Psychometric Properties of the Numerical Rating Scale to Assess Self-Reported Pain Intensity in Children and Adolescents: A Systematic Review, *Clin J Pain* 2017;33:376-83 doi:10.1097/AJP.00000000000406.
- Castarlenas E, Miró J, Sánchez-Rodríguez E. Is the verbal numerical rating scale a valid tool for assessing pain intensity in children below 8 years of age? *J Pain* 2013;14:297-304 doi:10.1016/j.jpain.2012.12.004.
- 59. McKinley S, Coote K, Stein-Parbury J. Development and testing of a Faces Scale for the assessment of anxiety in critically ill patients, *Journal of Advanced Nursing* 2003;41:73-9 doi:10.1046/j.1365-2648.2003.02508.x.
- 60. Spielberger CD, Sydeman SJ. State-trait anxiety inventory and state-trait anger expression inventory. Hillsdale, NJ: Lawrence Erlbaum Associates 1994:292-321.

- 61. Baxter AL, Watcha MF, Baxter WV, et al. Development and validation of a pictorial nausea rating scale for children. Pediatrics 2011;127:1542.
- 62. Gold JI, Mahrer NE. Is Virtual Reality Ready for Prime Time in the Medical Space? A Randomized Control Trial of Pediatric Virtual Reality for Acute Procedural Pain Management, Journal of pediatric psychology 2018;43 doi:10.1093/jpepsy/jsx129.
- 63. Hoffman HG, Patterson DR, Seibel E, et al. Virtual reality pain control during burn wound debridement in the hydrotank, The Clinical journal of pain 2008;24 doi:10.1097/AJP.0b013e318164d2cc.
- Jac ric psy seibel E, c nydrotank, The Ji8164d2ce. Committee of Medical. rw.icmje.org/recommendat. rfning-the-role-of-authors-and-64. ICMJE. International Committee of Medical Journal Editors. 2017. Available: http://www.icmje.org/recommendations/browse/roles-andresponsibilities/defining-the-role-of-authors-and-contributors.html [Accessed 03 Aug 2021].

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Page 25 of 55




VR Game Menu Easy/Novice

Title	Category	Content	Controller	Comments
Henry	Immersive 12 min	Henry is the story of a little hedgehog on his birthday.	None	Fun, magical, some movement
YouTube	Immersive Passive	Watch YouTube videos in VR.	Use the front trigger to browse and choose videos	Some videos might not be VR 360 videos can be dizzying
Myth: A Frozen Tale	Immersive 8 min	Watch the elemental spirits of air, fire, water and earth.	None	Some movement, Magical creatures
Color Space	Interactive	A virtual reality coloring book with sound.	 Left controller is the paint pallet Right controller selects color 	Calming, relaxing No movement
Tilt Brush	Interactive	Paint your own 3D world!	 Left controller: art tools Left joy-stick flips through art tools Right controller selects tool and draws 	Calming, relaxing No movement
Bonfire	Interactive 15 min	You've crash-landed on an alien planet and try to survive.	Front Trigger Right hand joystick	Rated: 10+ Some movement, Fight a giant slug

*Child can be lying down for any of these games

VR Game Menu Experienced

Title	Category	Content	Controller	Comments
Jurassic World	Immersive 7 min (Blue) 3 min (Apatosarus)	Watch Blue the dinosaur interact with other dinosaurs! * Choose Blue first then Apatosaurus	Front trigger to choose video. Use any button to go back to main menu	Be careful, you will interact with a T-rex! Can be lying down.
Tetris Effects	Interactive	Tetris like you've never seen it, or heard it, or felt it before! * Play Journey Mode	 L hand joy-stick moves block Right hand A or B to change orientation of the block Right hand trigger to change block option 	Some movement, Lights and music. Can be lying down.
Fruit Ninja	Interactive	Slice through flying fruits! * Only Arcade game can be played	Swipe fruits with dominant hand controller.	Not a lot of movement, Only the flying fruits. Need to be sitting up.
Moss	Interactive Requires knowledge of VR or garning	Action-adventure puzzle game. Help a young mouse explore a magical world. *Hint: Use index trigger to drag blue glowing boxes	Left hand joystick to move Right hand A to jump Right B to hit/attack Right hand A&B to avoid Double B to go back to menu	There will be puzzles you'll have to figure out! Need to be sitting up straight.
Vader Immortal I, II and III For	Interactive Requires knowledge of VR or ganning	Step into a galaxy far far away! Episode I: hone light saber skills Episode II: Learn to use the force Episode III: Master the skills of the Jedi *Light saber dojo in each episode is very fun! y - http://bmjopen.bmj.co	 Joy stick to hover where to move Left joy stick when in the dojo. To use the force: press the grab trigger and hover over the object, you can move it towards you or throw/aim away Hint: check your belt you may have objects (e.g. light saber) 	Need to be sitting up straight Rated: Teen - Star Wars graphics - Fighting with the force - Need to be able to sit up straight - Lots of virtual movement es.xhtml





A randomized controlled trial of virtual reality-based distraction for venipuncture-related distress in children: The VR Study

REB #: Pro00095418	Screening ID	Enrolment Date
PI: Dr. Samina Ali	VR	/ / <u>2 0</u> dd mmm yyyy

Pre-Screening

Date and Time of Triage	// dd mmm yyyy : (24 hour clock)
Child's Age	years
Child's Sex	E Female Male
Was the family approached for this study?	Yes No
If NO, specify reason and STOP HERE.	 Family refused overall consent to be approached for research Legal guardian not present RA busy with another study Did not meet eligibility criteria, specify Other, Specify
If YES, continue to Eligibility.	4



2
3
4
-
4 5 7 8 9 10
6
7
<i>'</i>
8
9
10
10
11
12
12
15
14
15
16
10
17
18
10
17
 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31
21
22
22
23
24
25
25
26
27
27
28
29
30
50
31
32
32 33
34 35 36 37
35
20
30
37
37 38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59

60

A randomized controlled trial of virtual reality-based distraction for venipuncture-related distress in children
The VR Study

REB #: Pro00095418	Screening ID	Enrolment Date
PI: Dr. Samina Ali	VR	/ / <u>2 0</u> dd mmm yyyy

Eligibility

Was verbal consent for screening obtained from the family?	🗌 Yes	🗌 No

Inclusion Criteria

1. Child aged 6-17 years	🗌 Yes	🗌 No		
2. Requires IV placement	🗌 Yes	🗌 No		
3. Will receive topical anesthetic cream for IV placement	🗌 Yes	🗌 No		
Exclusion Criteria				

Exclusion Criteria

1.	Medically unstable (i.e. CTAS 1, requires immediate IV insertion)	🗌 Yes	🗌 No
2.	Unconscious or not fully alert	🗌 Yes	🗌 No
3.	Visual, auditory or cognitive or mental health issues precluding safe interaction with the VR intervention	🗌 Yes	🗌 No
4.	Conditions that could be exacerbated by the VR environment (as reported by the family) a. <i>current</i> symptomatic nausea / vomiting / dizziness / migraine b. <i>history</i> of psychosis / hallucinations / epilepsy	🗌 Yes	🗌 No
5.	 Presence of an infection / injury which could contaminate the VR intervention equipment (as determined by the healthcare team) including but not limited to a. open wounds / infections of the head and neck area b. suspected or confirmed methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) colonization 	🗌 Yes	No
6.	Screens positive for 'influenza-like illness' (ILI) as per the current SCH ED screening criteria	🗌 Yes	🗌 No
7.	Child or Parental language barrier precluding the ability to understand and complete study assessments, in the absence of a native language translator	🗌 Yes	🗌 No
8.	Previous enrollment (of child OR parent) in this study	🗌 Yes	🗌 No
ls th	ne family eligible for the study?	Yes	🗌 No



REB #: Pro00095418	3 #: Pro00095418 Screening ID	
PI: Dr. Samina Ali	VR	// <u>2</u> 0/ dd mmm yyyy
nformed Consent		
as written informed cons	sent been obtained from the parent/ legal gua	rdian? 🗌 Yes 🗌
<u>NO,</u>		
Specify reason and STC	P HERE.	 Declined consent Declined assent Other, please specify
<u>'YES,</u>		
Specify the date and tim	e of Informed Consent:	// dd mmm yyyy : (24 hour clock)
Has a copy of the signed	informed consent been given to the family?	Yes No; specify:
Has written assent been	obtained from the child ?	 Yes No; specify: No, but verbal assent was obtained and documented Not required; child < 7y
Has a copy of the signed	d assent been given to the family?	Yes No; specify:
Note: Consent only needs entire duration of the study	nsent been provided by the clinical nurse ? to be provided by the clinical nurse once for the y (for all 80-90 participants). If consent has not with the clinical nurse, make sure a signed copy ment.	Yes No; specify:
Clinical Nurse Study ID I	Number:	



A randomized controlled trial of virtual reality-based distraction for venipuncture-related distress in children: The VR Study

REB #: Pro00095418	Screening ID	Enrolment Date
PI: Dr. Samina Ali	VR	/ / <u>2 0</u> dd mmm yyyy

Randomization

If the child satisfies the inclusion/ exclusion criteria and written informed consent has been provided, please RANDOMIZE the participant by clicking on the Randomize button below:

Study Arm	<u> </u>	□ VR Intervention□ Standard Care



A randomized controlled trial of virtual reality-based distraction for venipuncture-related distress in children: The VR Study

REB #: Pro00095418 Screening ID		Enrolment Date
PI: Dr. Samina Ali	VR	// <u>20</u> ddmmmyyyy

Demographics & History

Demographics

Parent/ Caregiver relationship to child	Mother
	Father
	Other; specify:
Parent / Caregiver Age	years; or 🗌 Prefer not to answer
Parent / Caregiver Sex	E Female
	Male
Parent / Caregiver Highest level of Education	Elementary School
	High School or some High School
	Diploma/ Certificate
	Some Post-Secondary/ University
	University/ Professional Degree
	Decline to answer
First three digits of postal code	(1 st 3 digits ONLY)
Do you identify your child as a member of an ethnic minority?	Yes
	No
· L)
Medical History	

Medical History

Was your child born prematurely?	Yes
	No
If yes, at how many weeks gestation?	weeks
Has your child ever been to the Emergency Department before	☐ Yes
today?	🗌 No
If yes, how many times:	times
Has your child ever been hospitalized?	☐ Yes
	🗌 No
If yes, how many times:	times
Has your child ever had a needle poke in their vein to draw	☐ Yes
blood or put in an intravenous (IV) line?	🗌 No



REB #: Pro00095418	Screening ID			Enrolment Date
PI: Dr. Samina Ali	VR			// <u>2 0</u> dd mmm yyyy
more than one occurrenc recent event) Choose a n	s your child during the proc e, ask the parent to recall to number between 1 and 5 that tress where 1 indicates 'no d as possible'	he most at best	□ 2 □ 3 □ 4	stress at all) stressed as possible)
Child Experience with Has your child played wit following devices before t	h/ used any of the	☐ Gaming (ex. Xbo: ☐ Virtual R (ex. Ocu	console k, Nintendo, F eality (VR) de	evice t, Samsung Gear VR,
If yes, how frequently?		7		
iPad/ iPod/ iPhone / Tablet:	Gaming console	VR device		Robot
 hours/ week Less than Once per week Less than 5 times in 	 hours/ week Less than Once per week Less than 5 times in total 	 ☐ Less tha week	ours/ week n Once per n 5 times in	 hours/ week Less than Once per week Less than 5 times in total



A randomized controlled trial of virtual reality-based distraction for venipuncture-related distress in children: The VR Study

REB #: Pro00095418	Screening ID	Enrolment Date
PI: Dr. Samina Ali	VR	/ / <u>2 0</u> ddmmyyyy


PRE-Procedure: Child Scores

NOTE: Begin the video recorder (iPad) approximately 5 minutes before the start of the IV procedure, and stop the recording 5 minutes after the end of the procedure.

Baseline Scores: Child

Heart Rate (record from Triage)	bpr	n	
Time pre-procedure scores collected	dd	/ mmm :	/
	(24 hou	ur clock)	
Pain Score: verbal Numerical Rating Scale (vNRS) "On a scale of 0 to 10, where 0 is no pain and 10 is the worst pain you can imagine, what is your pain level now?"	/ 10)	
Distress Score: Numerical Rating Scale "On a scale of 0 to 10, where 0 is no distress and 10 is the most distress you can imagine having, what is your distress level now?"	/ 10)	

"These faces are showing different amounts of being scared. This face [point to the left-most face] is not scared at all, this face is a little bit more scared [point to the second face from left], a bit more scared [sweep finger along scale], right up to the most scared possible [pint to the last face on the right]. Have a look at these faces and choose the one that shows how scared you are right now."







A randomized controlled trial of virtual reality-based distraction for venipuncture-related distress in children: The VR Study

REB #: Pro00095418	Screening ID	Enrolment Date
PI: Dr. Samina Ali	VR	/ / <u>2 0</u> dd mmm yyyy

PRE-Procedure: Parent / Caregiver STAI Questionnaire

We would ask that you complete the following questions as they relate to your feelings about your child's upcoming IV procedure, today. A number of statements which people have used to describe themselves are given below. Read each statement and then circle the appropriate number to indicate how you feel right now, that is, at this moment. There are no right or wrong answers. Do not spend too much time on any one statement but give the answer which seems to describe your feelings best.

	Not at all Somewhat Moderately so Very much so				
1.	I feel calm	1	2	3	4
2.	I feel secure	1	2	3	4
3.	I am tense	1	2	3	4
4.	I feel strained	1	2	3	4
5.		1	2	3	4
6.	I feel upset	1	2	3	4
7.	I am presently worrying over possible misfortunes	1	2	3	4
8.		1	2	3	4
9.	I feel frightened	1	2	3	4
10.	I feel comfortable	1	2	3	4
11.	I feel self-confident	1	2	3	4
12.		1	2	3	4
13.	I am jittery	1	2	3	4
14.	I feel indecisive	1	2	3	4
15.	I am relaxed	1	2	3	4
16.	I feel content	1	2	3	4
17.	I am worried	1	2	3	4
18.	I feel confused	1	2	3	4
19.	I feel steady	1	2	3	4
20.	I feel pleasant	1	2	3	4
	 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 	2. I feel secure. 3. I am tense. 4. I feel strained. 5. I feel at ease. 6. I feel upset. 7. I am presently worrying over possible misfortunes. 8. I feel satisfied. 9. I feel frightened. 10. I feel comfortable. 11. I feel self-confident. 12. I feel nervous. 13. I am jittery. 14. I feel indecisive. 15. I am relaxed. 16. I feel content. 17. I am worried. 18. I feel confused. 19. I feel steady.	Not at all Somewhat Moderately so Very much so 1 I feel calm	Not at all Somewhat Moderately so Very much so 1 I feel calm	Not at all Somewhat Moderately so Very much so 1 I feel calm. 1 2 3 2 I feel secure. 1 2 3 3 I am tense. 1 2 3 4 I feel strained. 1 2 3 5 I feel at ease. 1 2 3 6 I feel ypset. 1 2 3 7 I am presently worrying over possible misfortunes. 1 2 3 8 I feel satisfied. 1 2 3 9 I feel comfortable. 1 2 3 10 I feel self-confident. 1 2 3 11 I feel nervous. 1 2 3 12 I feel indecisive. 1 2 3 13 I am jittery. 1 2 3 14 I feel indecisive. 1 2 3 15 I am relaxed. <t< td=""></t<>



A randomized controlled trial of virtual reality-based distraction for venipuncture-related distress in children: The VR Study

REB #: Pro00095418	Screening ID	Enrolment Date
PI: Dr. Samina Ali	VR	// <u>20</u> ddmmmyyyy

DURING-Procedure

- Start the iPad video recording approximately 5 minutes prior to the start of the procedure.
- For children randomized to the VR group: Immediately after PRE-procedure scores and STAI are completed, research assistant will set up the VR equipment.
- The staff ED nurse will then begin the IV set-up

Start time of IV procedure:		_/	
(Defined as the time the staff nurse begins to clean the IV site)	dd	mmm	уууу
		_:	_
	(24 11	our clock)	
End time of IV procedure/ attempt: 🚫			
		/	/
(Defined as the last point of contact by the staff nurse (ex. taping cannula in place with or without arm board, wrapping arm with	dd	mmm	уууу
gauze and taping the gauze in place)		_:	_
	(24 h	our clock)	

Position of Child during IV attempt:	Sitting up Lying down (supine)		
Location of first IV attempt:	 Antecubital Fossa – RIGHT Antecubital Fossa – RIGHT Dorsum hand – RIGHT Dorsum hand – LEFT Other, specify 		
Was the first IV placement attempt successful?			
 If NO, how many attempts, in total, were made for the IV during this 'episode'? 	attempts		
Was an IV successfully placed during this 'episode'?	Yes No		

Any adverse events or side effects?	Yes No
Do not suggest any AEs to the participant; Instead, ask more general questions such as "how are you feeling?" or "are you having any side effects?" or "are you feeling any different than before?", and let the child answer spontaneously.	If " YES ", complete a separate entry for each AE on the AE Form



REB #: Pro00095418		Screening ID		Enrolment Date
PI: Dr. Samina Ali	VR			// <u>2</u> 0/ dd mmm yyyy
IMEDIATELY PO OTE: Post-procedure so ocedure is complete:	cores/ questionnair		-	<u>possible</u> after the
ost-procedure Score	es: Child			
Time post-procedure sc	ores collected			dd mmm yyyy
	0			:: (24 hour clock)
Pain Score: verbal Num 'On a scale of 0 to 10, v magine, what was your	where 0 is no pain a	and 10 is the wors	t pain you can	/ 10
Distress Score: Numerie "On a scale of 0 to 10, v you can imagine having <u>IV poke</u> "	where 0 is no distre	ess and 10 is the r		/ 10
scared at all, this face is [sweep finger along sca	ng different amoun s a little bit more sc le], right up to the r	ts of being scared ared [point to the most scared possi	second face from ole [pint to the la	to the left-most face] is not in left], a bit more scared ist face on the right]. Have ing the needle / IV poke."
call that feeling of being all, who feel a little bit n	felt like you were g sick to the stomac auseated, who feel ble to feel." [Point to	joing to throw up b h nausea. These even more nause	efore? How did aces show child ated, and these	your tummy feel then? We ren who feel no nausea at are children who have the .] "Which face is more like



REB #: Pro00095418	Screening ID	Enrolment Date
PI: Dr. Samina Ali	VR	/ / <u>2 0</u> ddmmmyyyy
	were you with the IV start today, on a scale of 1 to a at all happy" and 5 means "Very happy"?	5, 1 "Not at all happy 2 3 4 5 "Very happy"
	where 1 means "Not at all happy" and 5 means appy were you <u>with the pain treatment</u> for your IV	 ☐ 1 "Not at all happy" ☐ 2 ☐ 3 ☐ 4 ☐ 5 "Very happy"
Did the [distraction /	toys / VR goggles] help you today?	 Yes, it helped No, it didn't help I'm not sure
	t an IV or needle poke again, would you want to us n / toys / VR goggles] again?	se Yes, I would No, I wouldn't I'm not sure
	ne why/ why not?	

As soon as possible after completion of procedure, research assistant to give:

1. Post-Procedure Parent STAI and Satisfaction Questionnaire to parent/ caregiver

2. Nurse Satisfaction Questionnaire to staff ED nurse





 A randomized controlled trial of virtual reality-based distraction for venipuncture-related distress in children: The VR Study

REB #: Pro00095418	Screening ID	Enrolment Date
PI: Dr. Samina Ali	VR	/ / <u>2 0</u> dd mmm yyyy

POST-Procedure: Parent / Caregiver STAI Questionnaire

We would ask that you complete the following questions as they relate to your feelings about your child's IV procedure that just happened. A number of statements which people have used to describe themselves are given below. Read each statement and then circle the appropriate number to indicate how you feel right now, that is, at this moment. There are no right or wrong answers. Do not spend too much time on any one statement but give the answer which seems to describe your feelings best.

10		13				
19 20		I4 Not at all Somewhat Moderately so Very much so				
20						
22 23	1.	I feel calm	1	2	3	4
24	2.	I feel secure	1	2	3	4
25 26	3.	I am tense	1	2	3	4
27 28	4.	I feel strained	1	2	3	4
29 30	5.	I feel at ease	1	2	3	4
31	6.	I feel upset	1	2	3	4
32 33	7.	I am presently worrying over possible misfortunes	1	2	3	4
34 35	8.	I feel satisfied	1	2	3	4
36	9.	I feel frightened	1	2	3	4
37 38	10.	I feel comfortable	1	2	3	4
39 40	11.	I feel self-confident	1	2	3	4
41	12.	I feel nervous	1	2	3	4
42 43	13.	I am jittery	1	2	3	4
44 45	14.	I feel indecisive	1	2	3	4
46	15.	I am relaxed	1	2	3	4
47 48	16.	I feel content	1	2	3	4
49 50	17.	I am worried	1	2	3	4
51	18.	I feel confused	1	2	3	4
52 53	19.	I feel steady	1	2	3	4
54 55	20.	I feel pleasant	1	2	3	4



REB #: Pro00095418		Screening ID		Enrolment Date
PI: Dr. Samina Ali	VR		-	/ / <u>2 0</u> ddmmmy
OST-Procedure:	Caregiver Sati	sfaction Que	stionnaire	
) Please rate your ov	verall satisfaction	with your child's	IV start:	
Very Dissatisfied 1	Dissatisfied 2	Neutral 3 □	Satisfied 4	Very Satisfied 5
Please Explain: _				
	0	0		
) Please rate your sa	atisfaction with the	management of	your child's pain f	for their IV start:
Very Dissatisfied 1	Dissatisfied 2	Neutral 3	Satisfied 4	Very Satisfied 5
Please Explain: _			4	
			<u> </u>	
Would you use the future?	same methods to	manage your ch	ild's pain from nee	edle pokes in the
Yes No				
Why / Why not?				
	Thank you for you it is	r participation in very much appre		ly,
VR Study CRF	N N	Version July 15. 20	20	Page 13 of 2



REB #: Pro00095418			Screening ID		Enrolment	Date
PI:	Dr. Samina Ali	VR		_	/ ddmmm	/ <u>2 0</u>
lu	rse Satisfactio	on Questionnair	e (VR Group)			
1)	Overall, how easy	or difficult was it to pe	erform the IV inse	rtion for this child?		
	Very Easy 1	Easy 2	Neutral 3	Difficult	Very Difficul 5	lt
2)	Please rate your s	atisfaction with this ch	nild's IV start:			
	Very Dissatisfied 1	Dissatisfied	Neutral	Satisfied 4 □	Very Satisfied 5	
3)	from IV insertion in Yes No		R.	•		SS
1)	Could you please	rate the following on a	a scale of 1-5, whe	ere 1= Not at all an		_
	Your willingness to pain and distress i The degree to whi The degree to whi	action with the Virtual o use the VR device to n the future ch the VR device impr ch the VR improved y ch the VR disrupted y	o manage another roved the child's e your ability to inse	child's IV	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	5
5)		that was used during imately how much tim	•			e IV?
		also that you would lik	e to tell us todav	about vour experi	ence inserting ar	n IV



A randomized controlled trial of virtual reality-based distraction for venipuncture-related distress in children: The VR Study			
REB #: Pro00095418	Screening ID	Enrolment Date	
PI: Dr. Samina Ali	VR	// <u>2 0</u> dd mmm y	
7) How many years of	of practice do you have as a nurse (all settings)?	N/A	
8) How many years o	of practice do you have as a nurse in the ED?	N/A	
9) Please indicate th	e amount of time spent in the pediatric emergency dep	artment (PED):	
	ny time is spent in the pediatric ED		
	my time is spent in the pediatric ED		
	my time is spent in the pediatric ED		
∐ 76-100% c	of my time is spent in the pediatric ED		
	ur position if other than attending ED nurse (e.g., IV nu	rse, attending ED	
physician, residen	it, physician or nurse from other service [specify], etc):		
	/		
	Thank You!!		
		_ •·	
VR Study CRF	Version July 15, 2020	Page 15 of 2	



	EB #: Pro00095418 Screening ID			E	Enrolment	Date	
PI: Dr. Sam	ina Ali	VR		-	dd	/ mmm	/ <u>2 0</u> yy
Nurse S	Satisfactio	n Questionnai	re (Standard (Care Group)			
I) Overall	, how easy or	difficult was it to pe	erform the IV insert	tion for this child?	?		
Vei	ry Easy	Easy	Neutral	Difficult	Ver	ry Difficul	t
		2	3 □	4		5 □	
2) Please	rate your sat	isfaction with this ch	ild's IV start:				
	Very				_	Very	
Diss	satisfied 1	Dissatisfied 2	Neutral 3	Satisfied 4	S	Satisfied 5	
		Ĺ	o Č				
) Could	you please rat	te the following on a	scale of 1-5, whe	re 1= Not at all a	nd <mark>5=Ve</mark> i	ry much	
				1	2	3 4	5
Your wi	illingness to u	tion with the pain ma se a similar pain ma in and distress in the	anagement plan to	_			
anothei	•						
	0	the pain manageme	ent plan improved	the child's			
The deg experie	nce gree to which	the pain management					
The dee experie The dee to inser	nce gree to which t the IV gree to which		ent plan improved	l your ability			
The deg experie The deg to inser The deg to inser 5) Did the the time	nce gree to which t the IV gree to which t the IV Standard of e required to i	the pain management the pain management Care pain management insert the IV?	ent plan improved ent plan disrupted nent plan that was	I your ability			L D Se
The deg experie The deg to inser The deg to inser 5) Did the the time	nce gree to which t the IV gree to which t the IV Standard of e required to i	the pain manageme the pain manageme Care pain managen	ent plan improved ent plan disrupted nent plan that was	I your ability		L L L L re increas minutes)	L L Se



 7) How many years of practice do you have as a nurse (all settings)? N/A 8) How many years of practice do you have as a nurse in the ED? N/A 9) Please indicate the amount of time spent in the pediatric emergency department (PED): 0-25% of my time is spent in the pediatric ED 26-50% of my time is spent in the pediatric ED 51-75% of my time is spent in the pediatric ED 76-100% of my time is spent in the pediatric ED 	dd mmm yy 7) How many years of practice do you have as a nurse (all settings)? N/A 8) How many years of practice do you have as a nurse in the ED? N/A 9) Please indicate the amount of time spent in the pediatric emergency department (PED): N/A 9) Please indicate the amount of time spent in the pediatric ED 0-25% of my time is spent in the pediatric ED 26-50% of my time is spent in the pediatric ED 51-75% of my time is spent in the pediatric ED 10) Please specify your position if other than attending ED nurse (e.g., IV nurse, attending ED physician, resident, physician or nurse from other service [specify], etc): Thank You!!	REB #: Pro00095418	Screening ID	Enrolment Date
 B) How many years of practice do you have as a nurse in the ED? N/A Please indicate the amount of time spent in the pediatric emergency department (PED): 0-25% of my time is spent in the pediatric ED 26-50% of my time is spent in the pediatric ED 51-75% of my time is spent in the pediatric ED 76-100% of my time is spent in the pediatric ED 10) Please specify your position if other than attending ED nurse (e.g., IV nurse, attending ED physician, resident, physician or nurse from other service [specify], etc): 	8) How many years of practice do you have as a nurse in the ED? N/A 9) Please indicate the amount of time spent in the pediatric emergency department (PED): 0-25% of my time is spent in the pediatric ED 26-50% of my time is spent in the pediatric ED 51-75% of my time is spent in the pediatric ED 76-100% of my time is spent in the pediatric ED 10) Please specify your position if other than attending ED nurse (e.g., IV nurse, attending ED physician, resident, physician or nurse from other service [specify], etc): Thank You!!	PI: Dr. Samina Ali	VR	
 9) Please indicate the amount of time spent in the pediatric emergency department (PED): 0-25% of my time is spent in the pediatric ED 26-50% of my time is spent in the pediatric ED 51-75% of my time is spent in the pediatric ED 76-100% of my time is spent in the pediatric ED 10) Please specify your position if other than attending ED nurse (e.g., IV nurse, attending ED physician, resident, physician or nurse from other service [specify], etc): Thank You!! 	 9) Please indicate the amount of time spent in the pediatric emergency department (PED): 0-25% of my time is spent in the pediatric ED 26-50% of my time is spent in the pediatric ED 51-75% of my time is spent in the pediatric ED 10) Please specify your position if other than attending ED nurse (e.g., IV nurse, attending ED physician, resident, physician or nurse from other service [specify], etc): Thank You!!	7) How many years o	of practice do you have as a nurse (all settings)?	N/A
 0-25% of my time is spent in the pediatric ED 26-50% of my time is spent in the pediatric ED 51-75% of my time is spent in the pediatric ED 76-100% of my time is spent in the pediatric ED 10) Please specify your position if other than attending ED nurse (e.g., IV nurse, attending ED physician, resident, physician or nurse from other service [specify], etc): Thank You!!	 0-25% of my time is spent in the pediatric ED 26-50% of my time is spent in the pediatric ED 51-75% of my time is spent in the pediatric ED 76-100% of my time is spent in the pediatric ED 10) Please specify your position if other than attending ED nurse (e.g., IV nurse, attending ED physician, resident, physician or nurse from other service [specify], etc): Thank You!!	8) How many years o	of practice do you have as a nurse in the ED?	□ N/A
 26-50% of my time is spent in the pediatric ED 51-75% of my time is spent in the pediatric ED 76-100% of my time is spent in the pediatric ED 10) Please specify your position if other than attending ED nurse (e.g., IV nurse, attending ED physician, resident, physician or nurse from other service [specify], etc): Thank You!!	 26-50% of my time is spent in the pediatric ED 51-75% of my time is spent in the pediatric ED 76-100% of my time is spent in the pediatric ED 10) Please specify your position if other than attending ED nurse (e.g., IV nurse, attending ED physician, resident, physician or nurse from other service [specify], etc): Thank You!!	9) Please indicate th	e amount of time spent in the pediatric emergency depa	rtment (PED):
 26-50% of my time is spent in the pediatric ED 51-75% of my time is spent in the pediatric ED 76-100% of my time is spent in the pediatric ED 10) Please specify your position if other than attending ED nurse (e.g., IV nurse, attending ED physician, resident, physician or nurse from other service [specify], etc): Thank You!!	 26-50% of my time is spent in the pediatric ED 51-75% of my time is spent in the pediatric ED 76-100% of my time is spent in the pediatric ED 10) Please specify your position if other than attending ED nurse (e.g., IV nurse, attending ED physician, resident, physician or nurse from other service [specify], etc): Thank You!!	0-25% of r	ny time is spent in the pediatric ED	
 51-75% of my time is spent in the pediatric ED 76-100% of my time is spent in the pediatric ED 10) Please specify your position if other than attending ED nurse (e.g., IV nurse, attending ED physician, resident, physician or nurse from other service [specify], etc): Thank You!!	 51-75% of my time is spent in the pediatric ED 76-100% of my time is spent in the pediatric ED 10) Please specify your position if other than attending ED nurse (e.g., IV nurse, attending ED physician, resident, physician or nurse from other service [specify], etc): Thank You!!			
76-100% of my time is spent in the pediatric ED 10) Please specify your position if other than attending ED nurse (e.g., IV nurse, attending ED physician, resident, physician or nurse from other service [specify], etc): Thank You!!	76-100% of my time is spent in the pediatric ED 10) Please specify your position if other than attending ED nurse (e.g., IV nurse, attending ED physician, resident, physician or nurse from other service [specify], etc): Thank You!!			
physician, resident, physician or nurse from other service [specify], etc): Thank You!!	physician, resident, physician or nurse from other service [specify], etc): Thank You!!			
physician, resident, physician or nurse from other service [specify], etc): Thank You!!	physician, resident, physician or nurse from other service [specify], etc): Thank You!!			
Thank You!!	Thank You!!			se, attending ED
		physician, residen	t, physician or nurse from other service [specify], etc):	
		_		
			\sim	
			Thank You!!	



REB #: Pro00095418	Screening	ID Enrolment Date
PI: Dr. Samina Ali	VR	/ / <u>2 0</u> / dd mmm y
Discharge Informatio	n	
Disposition		Discharged Home
		Admitted
		Other,
		/
Date & Time of Discharge f	rom the ED	dd mmm yyyy
5		:
		(24 hour clock)
Length of Stay in ED (calcu	lated field):	hours
Discharge Diagnosis		



REB #: Pro00095418	Screening ID	Enrolment Date
PI: Dr. Samina Ali	VR	// <u>2 0</u> / dd mmyyy
RA Satisfaction G	Questionnaire (For Standard Care group,	answer Q6 ONLY)
) Could you please rat	te the following on a scale of 1-5, where 1= Not a	t all and 5=Very much
		1 2 3 4 5
	ction with the Virtual Reality (VR) device today	
Ease of set-up of th		
Your satisfaction wi device	ith the amount of time it took to set up the VR	
Your desire to work	with the VR device again	
	nuch time was needed to set up the VR device w and questionnaire time)	ith the child, today?
minutes		
VR GogglesControllerHeadphone		
	s / neadset kept on for the entire duration of the	procedure:
□ No		
i) What applications / g	game(s) did the child play during the procedure?	
Check all that apply. If	et / Smartphone 🗌 Other; s	
) Did you have any teo	chnical or other issues with operating / handing th y:	• •
Yes; specify		



A randomized controlled trial of virtual reality-based distraction for venipuncture-related distress in children:

The	VR	Stu	dy
-----	----	-----	----

REB #: Pro00095418	Screening ID	Enrolment Date
PI: Dr. Samina Ali	VR	/ / <u>2 0</u> dd mmm yyyy

Adverse Events Log

	To be filled out by Research Assistant						be filled out	by Site Investig	ator	
No.	Description of Adverse Event	Onset Date & Time (dd/mmm/ yyyy HH:MM)	Action Taken 1.None 2.Medication 3.New or Prolonged Hospitalization 4.Procedure / Surgery 5.Other, specify	Outcome 1. Resolved 2. Resolved with Sequelae 3. Resolving 4. Unresolved 5. Fatal 6. Lost to follow-up	Date & Time Resolved (dd/mmm/ yyyy HH:MM)	Intensity grade: 1. Mild 2. Moderate 3. Severe	Expected AE? Y / N	Relationship to Study 1.Unrelated 2.Unlikely 3.Possible 4.Probable 5.Definite	SAE? Y/N	Site PI Initial
1				191	ien					
2						0nj				
3										



A randomized controlled trial of virtual reality-based distraction for venipuncture-related distress in children: The VR Study

REB #: Pro00095418	Screening ID	Enrolment Date
PI: Dr. Samina Ali	VR	/ / <u>2 0</u> dd mmm yyyy

Early Withdrawal

ONLY fill out this form in the event of an early withdrawal

dd mmm yyyy
Adverse Event / Serious Adverse Event Death Withdrawal of Consent / Assent Protocol Violation, Specify
Other, Specify
☐ Yes ☐ No ☐ Yes ☐ No
2

Reporting checklist for protocol of a clinical trial.

		Reporting Item	Page Number
Title	<u>#1</u>	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	<u>#2a</u>	Trial identifier and registry name. If not yet registered, name of intended registry	1
Trial registration: data set	<u>#2b</u>	All items from the World Health Organization Trial Registration Data Set	5-7 (Table 1)
Protocol version	<u>#3</u>	Date and version identifier	2
Funding	<u>#4</u>	Sources and types of financial, material, and other support	14
Roles and responsibilities: contributorship	<u>#5a</u>	Names, affiliations, and roles of protocol contributors	15
Roles and responsibilities: sponsor contact information	<u>#5b</u>	Name and contact information for the trial sponsor	5
Roles and responsibilities: sponsor and funder	<u>#5c</u>	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	14
Roles and responsibilities: committees	<u>#5d</u>	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or	N/A
	For peer	review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

		BMJ Open	Page 50 of 55
		groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	
Background and rationale	<u>#6a</u>	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	4-5
Background and ationale: choice of comparators	<u>#6b</u>	Explanation for choice of comparators	7-8
Objectives	#7	Specific objectives or hypotheses	5
Trial design	<u>#8</u>	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, non-inferiority, exploratory)	5
Study setting	<u>#9</u>	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	7
Eligibility criteria	<u>#10</u>	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	7
Interventions: description	<u>#11a</u>	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	7-8
Interventions: modifications	<u>#11b</u>	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving / worsening disease)	9,13
	For peer	review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2 3 4 5 6 7	Interventions: adherance	<u>#11c</u>	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return; laboratory tests)	9
8 9 10 11	Interventions: concomitant care	<u>#11d</u>	Relevant concomitant care and interventions that are permitted or prohibited during the trial	8
12 13 14 15 16 17 18 19 20 21 22 23 24	Outcomes	<u>#12</u>	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	10-11
24 25 26 27 28 29 30 31 32	Participant timeline	<u>#13</u>	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	8-9 and Figure 3
33 34 35 36 37 38 39 40	Sample size	<u>#14</u>	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	11
41 42 43 44	Recruitment	<u>#15</u>	Strategies for achieving adequate participant enrolment to reach target sample size	11
45 46 47 48 49 50 51 52 53 54 55 56 57 58	Allocation: sequence generation	<u>#16a</u>	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	8
59 60		For peer	review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

Page 52 of 55

BMJ Open

1 2 3 4 5 6 7 8 9 10 11 2 3 4 5 6 7 8 9 10 11 2 3 4 5 6 7 8 9 10 11 2 3 4 5 6 7 8 9 10 11 2 3 4 5 6 7 8 9 0 11 2 2 3 4 5 6 7 8 9 0 11 2 3 3 4 5 6 7 8 9 0 11 2 3 4 5 6 7 8 9 0 11 2 2 3 4 5 6 7 8 9 0 11 2 2 3 4 5 6 7 8 9 0 11 2 2 3 4 5 6 7 8 9 0 11 2 2 3 4 5 6 7 8 9 0 11 2 2 3 4 5 6 7 8 9 0 11 2 2 3 4 5 6 7 8 9 0 11 2 2 3 4 5 6 7 8 9 0 11 2 2 3 4 5 6 7 8 9 0 1 2 2 3 4 5 6 7 8 9 0 1 2 2 3 4 5 6 7 8 9 0 1 2 2 3 4 5 6 7 8 9 0 1 2 2 3 4 5 6 7 8 9 0 1 2 2 3 4 5 6 7 8 9 0 1 2 2 3 4 5 6 7 8 9 0 1 2 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 3 4 5 6 7 8 9 0 1 2 3 3 4 5 6 7 8 9 0 1 2 3 3 4 5 6 7 8 9 0 1 2 3 3 4 5 6 7 8 9 0 1 2 3 3 4 5 6 7 8 9 0 1 2 3 3 4 5 6 7 8 9 0 1 2 3 4 5 5 6 7 8 9 0 1 2 3 3 4 5 5 6 7 8 9 0 1 2 3 4 5 5 6 7 8 9 0 1 2 5 3 4 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	Allocation concealment mechanism	<u>#16b</u>	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	8
	Allocation: implementation	<u>#16c</u>	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	8
	Blinding (masking)	<u>#17a</u>	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	8
	Blinding (masking): emergency unblinding	<u>#17b</u>	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	N/A
	Data collection plan	<u>#18a</u>	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	8-9 and Appendix 2 for Case Report Form
	Data collection plan: retention	<u>#18b</u>	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	9
60		For peer	review only - http://bmjopen.bmj.com/site/about/guidelines.x	html

Page 53 of 55

BMJ Open

1 2 3 4 5 6 7 8 9 10 11	Data management	<u>#19</u>	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	12
12 13 14 15 16 17 18	Statistics: outcomes	<u>#20a</u>	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	11
19 20 21 22	Statistics: additional analyses	<u>#20b</u>	Methods for any additional analyses (eg, subgroup and adjusted analyses)	11
23 24 25 26 27 28 29	Statistics: analysis population and missing data	<u>#20c</u>	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	11
30 31 32 33 34 35 36 37 38 39 40 41 42	Data monitoring: formal committee	<u>#21a</u>	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	N/A
43 44 45 46 47 48 49	Data monitoring: interim analysis	<u>#21b</u>	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	N/A
50 51 52 53 54 55 56 57 58 59	Harms	<u>#22</u>	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	11
60		For peer	review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

	BMJ Open
<u>#23</u>	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor
<u>#24</u>	Plans for seeking research ethics committee / institutional review board (REC / IRB) approval
<u>#25</u>	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC / IRBs, trial participants, trial registries, journals, regulators)

Consent or assent	#26a	Who will obtain informed consent or assent from	8
Consent of assent	<u>#20a</u>	who will obtain informed consent of assent from	0
		potential trial participants or authorised	
		surrogates, and how (see Item 32)	
Consent or assent:	<u>#26b</u>	Additional consent provisions for collection and	N/A
ancillary studies		use of participant data and biological specimens	
		in ancillary studies, if applicable	
Confidentiality	#27	How personal information about potential and	12

0				
9	Confidentiality	<u>#27</u>	How personal information about potential and	12
1			enrolled participants will be collected, shared,	
2			and maintained in order to protect confidentiality	
3 4			before, during, and after the trial	
5 6	Declaration of	<u>#28</u>	Financial and other competing interests for	13
7 8	interests		principal investigators for the overall trial and	
9			each study site	
0 1 2	Data access	<u>#29</u>	Statement of who will have access to the final	Table 1
3			trial dataset, and disclosure of contractual	

		investigators	
Ancillary and post trial care	<u>#30</u>	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	N/A
Dissemination policy: trial results	<u>#31a</u>	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other	13

agreements that limit such access for

N/A

14-15

12-13

Auditing

approval

Protocol

amendments

Research ethics

60

BMJ Open

		results databases, or other data sharing arrangements), including any publication restrictions	
3Dissemination policy: authorship	<u>#31b</u>	Authorship eligibility guidelines and any intended use of professional writers	15-16
Dissemination policy: reproducible research	<u>#31c</u>	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	Table 1
Informed consent materials	<u>#32</u>	Model consent form and other related documentation given to participants and authorised surrogates	Appendix 1
Biological specimens	<u>#33</u>	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	N/A